1

A genome-wide association study of chronic ALT-based non-alcoholic

2 fatty liver disease in the Million Veteran Program with histological

3 and radiological validation

4	Marijana Vujkovic ^{1,2,°}	[*] , Shweta Ramdas ^{3,}	[*] , Kimberly M. Lorenz ^{1,3,4}	, Xiuqing Guo	⁵, Rebecca
---	------------------------------------	--	--	---------------	------------

- 5 Darlay⁶, Heather J. Cordell⁶, Jing He⁷, Yevgeniy Gindin⁸, Chuhan Chung⁸, Rob P Meyers⁸, Carolin
- 6 V. Schneider³, Joseph Park^{3,2}, Kyung M. Lee⁹, Marina Serper¹, Rotonya M. Carr², David E.
- 7 Kaplan¹, Mary E. Haas¹⁰, Matthew T. MacLean³, Walter R. Witschey¹¹, Xiang
- 8 Zhu^{12,13,14,15}, Catherine Tcheandjieu^{12,16}, Rachel L. Kember^{17,18}, Henry R. Kranzler^{17,18}, Anurag
- 9 Verma^{1,3}, Ayush Giri¹⁹, Derek M. Klarin^{20,21,22}, Yan V. Sun^{23,24}, Jie Huang²⁵, Jennifer
- 10 Huffman²¹, Kate Townsend Creasy³, Nicholas J. Hand³, Ching-Ti Liu²⁶, Michelle T. Long²⁷, Jie
- 11 Yao⁵, Matthew Budoff²⁸, Jingyi Tan⁵, Xiaohui Li⁵, Henry J. Lin⁵, Yii-Der Ida Chen⁵, Kent D.
- 12 Taylor⁵, Ruey-Kang Chang⁵, Ronald M. Krauss²⁹, Silvia Vilarinho³⁰, Joseph Brancale³⁰, Jonas B.
- 13 Nielsen³¹, Adam E. Locke³¹, Marcus B. Jones³¹, Niek Verweij³¹, Aris Baras³¹, K. Rajender
- 14 Reddy², Brent A. Neuschwander-Tetri³², Jeffrey B. Schwimmer³³, Arun J. Sanyal³⁴, Naga
- 15 Chalasani³⁵, Katherine A. Ryan³⁶, Braxton D. Mitchell³⁷, Dipender Gill³⁸, Andrew D.
- 16 Wells^{39,40}, Elisabetta Manduchi⁴¹, Yedidya Saiman⁴², Nadim Mahmud⁴², Donald R.
- 17 Miller^{43,44}, Peter D. Reaven^{45,46}, Lawrence S. Phillips^{23,47}, Sumitra Muralidhar⁴⁸, Scott L.
- 18 DuVall^{9,49}, Jennifer S. Lee^{12,16}, Themistocles L. Assimes^{12,16}, Saiju Pyarajan^{21,50,51}, Kelly
- 19 Cho^{21,50}, Todd L. Edwards^{52,53}, Scott M. Damrauer^{1,54}, Peter W. Wilson^{23,55}, J. Michael
- 20 Gaziano^{21,50}, Christopher J. O'Donnell^{21,50,51}, Amit V. Khera^{20,22,51}, Struan F.A.
- 21 Grant^{56,40}, Christopher D. Brown³, Philip S. Tsao^{12,16}, Danish Saleheen^{57,58,59}, Luca A. Lotta³¹, Lisa

2

- 22 Bastarache⁷, Quentin M. Anstee⁶⁰, Ann K. Daly⁶¹, James B. Meigs^{22,51,62}, Jerome I. Rotter⁵, Julie
- 23 A. Lynch^{9,49,63}, Regeneron Genetics Center, DiscovEHR Collaboration, EPoS Consortium
- 24 Investigators, VA Million Veteran Program, Daniel J. Rader^{2,3,*}, Benjamin F.
- 25 Voight^{1,3,4,64,*}, Kyong-Mi Chang^{1,4,*}
- 26
- 27 *These authors contributed equally
- 28

29 Affiliations

30 ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA, ²Department of

- 31 Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,
- 32 USA, ³Department of Genetics, University of Pennsylvania Perelman School of Medicine,
- 33 Philadelphia, PA, USA, ⁴Department of Systems Pharmacology and Translational Therapeutics,
- 34 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, ^sThe Institute for
- 35 Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist
- 36 Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA,
- 37 USA, ⁶Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne,
- 38 UK, ⁷Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN,
- 39 USA, [®]Bioinformatics and Clinical Data Science, Gilead Sciences, Inc., Foster City, CA, USA, [®]VA
- 40 Salt Lake City Health Care System, Salt Lake City, UT, USA, ¹⁰Broad Institute of MIT and Harvard,
- 41 Cambridge, MA, USA, ¹¹Department of Radiology, University of Pennsylvania Perelman School of
- 42 Medicine, Philadelphia, PA, USA, ¹²VA Palo Alto Health Care System, Palo Alto, CA,
- 43 USA, ¹³Department of Statistics, The Pennsylvania State University, University Park, PA,
- 44 USA, ¹⁴Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA,
- 45 USA, ¹⁵Department of Statistics, Stanford University, Stanford, CA, USA, ¹⁶Department of
- 46 Medicine, Stanford University School of Medicine, Stanford, CA, USA, ¹⁷Mental Illness Research
- 47 Education and Clinical Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA,
- 48 USA, ¹⁸Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
- 49 Philadelphia, PA, USA, ¹⁹Department of Obstetrics and Gynecology, Vanderbilt University Medical
- 50 Center, Nashville, TN, USA, ²⁰Center for Genomic Medicine, Massachusetts General Hospital,
- 51 Boston, MA, USA, ²¹VA Boston Healthcare System, Boston, MA, USA, ²²Program in Medical and
- 52 Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA, ²³Atlanta VA
- 53 Medical Center, Decatur, GA, USA, ²⁴Department of Epidemiology, Emory University Rollins
- 54 School of Public Health, Atlanta, GA, USA, ²⁵Department of Global Health, School of Public
- 55 Health, Peking University, Beijing, China, ²⁶Department of Biostatistics, Boston University School

3

of Public Health, Boston, MA, USA, ²⁷Department of Medicine, Section of Gastroenterology, 56 57 Boston University School of Medicine, Boston, MA, USA, ²⁸ Department of Cardiology, The 58 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, 59 USA, ²⁹Department of Medicine, Children's Hospital Oakland Research Institute, Oakland, CA, 60 USA, ³⁰Departments of Internal Medicine, Section of Digestive Diseases, and of Pathology, Yale 61 School of Medicine, New Haven, CT, USA, ³¹Regeneron Genetics Center, Tarrytown, NY, 62 USA, ³²Department of Internal Medicine, Saint Louis University, St. Louis, MO, USA, ³³Department 63 of Pediatrics, University of California San Diego, La Jolla, CA, USA, ³⁴Department of Internal 64 Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, 65 USA, ³⁵Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, 66 USA, ³⁶VISN 5 Capitol Health Care Network Mental Illness Research Education and Clinical 67 Center, Baltimore, MD, USA, ³⁷Program for Personalized and Genomic Medicine, Division of 68 Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA, ³⁸Department of Epidemiology and Biostatistics, School of 69 70 Public Health, Imperial College London, London, UK, ³⁹Department of Pathology and Laboratory 71 Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 72 USA, ⁴⁰Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, 73 USA, ⁴¹Institute for Biomedical Informatics, University of Pennsylvania Perelman School of 74 Medicine, Philadelphia, PA, USA, ⁴²Department of Medicine, Division of Gastroenterology, 75 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, ⁴³Edith Nourse 76 Rogers Memorial VA Hospital, Bedford, MA, USA, ⁴⁴Center for Population Health, University of 77 Massachusetts, Lowell, MA, USA, ⁴⁵Phoenix VA Health Care System, Phoenix, AZ, USA, ⁴⁶College of 78 Medicine, University of Arizona, Tuscon, AZ, USA, ⁴⁷Division of Endocrinology, Emory University 79 School of Medicine, Atlanta, GA, USA, ⁴⁸Office of Research and Development, Veterans Health 80 Administration, Washington, DC, USA, ⁴⁹Department of Medicine, University of Utah School of 81 Medicine, Salt Lake City, UT, USA, ⁵⁰Department of Medicine, Brigham Women's Hospital, Boston, 82 MA, USA, ⁵¹Department of Medicine, Harvard Medical School, Boston, MA, USA, ⁵²Nashville VA 83 Medical Center, Nashville, TN, USA, ⁵³Vanderbilt Genetics Institute, Vanderbilt University Medical 84 Center, Nashville, TN, USA, ⁵⁴Department of Surgery, University of Pennsylvania Perelman School 85 of Medicine, Philadelphia, PA, USA, ⁵⁵Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA, ⁵⁶Department of Pediatrics, University of Pennsylvania Perelman 86 87 School of Medicine, Philadelphia, PA, USA, ⁵⁷Department of Medicine, Columbia University Irving 88 Medical Center, New York, NY, USA, ⁵⁸Department of Cardiology, Columbia University Irving 89 Medical Center, New York, NY, USA, ⁵⁹Center for Non-Communicable Diseases, Karachi, Sindh, 90 Pakistan, 60 Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle 91 University, Newcastle upon Tyne, UK, ⁶¹Newcastle NIHR Biomedical Research Centre, Newcastle 92 upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, ⁶²Division of General 93 Internal Medicine, Massachusetts General Hospital, Boston, MA, USA, 6College of Nursing and 94 Health Sciences, University of Massachusetts, Lowell, MA, USA, 64Institute of Translational 95 Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, 96 Philadelphia, PA, USA

4

97 Abstract

98 Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease. Using a 99 proxy NAFLD definition of chronic alanine aminotransferase elevation (cALT) without other liver 100 diseases, we performed a trans-ancestry genome-wide association study in the Million Veteran 101 Program including 90,408 cALT cases and 128,187 controls. In the Discovery stage, seventy-102 seven loci exceeded genome-wide significance - including 25 without prior NAFLD or ALT 103 associations – with one additional locus identified in European-only and two in African-American-only analyses ($P < 5 \times 10^{-8}$). External replication in cohorts with NAFLD defined by 104 105 histology (7,397 cases, 56,785 controls) or liver fat extracted from radiologic imaging 106 (n=44,289) validated 17 SNPs $(P<6.5x10^{-4})$ of which 9 were novel (TRIB1, PPARG, MTTP)107 SERPINA1, FTO, IL1RN, COBLL1, APOH, and IFI30). Pleiotropy analysis showed that 61 of 77 108 trans-ancestry and all 17 validated SNPs were jointly associated with metabolic and/or inflammatory traits, revealing a complex model of genetic architecture. Our approach 109 110 integrating cALT, histology and imaging reveals new insights into genetic liability to NAFLD.

111

5

113 Introduction

114 Chronic liver disease with progression to cirrhosis and hepatocellular carcinoma is a global 115 health issue¹. In particular, nonalcoholic fatty liver disease (NAFLD) – a hepatic phenotype 116 associated with metabolic syndrome and insulin resistance – is an increasingly common cause of chronic liver disease with an estimated world prevalence of 25% among adults¹⁻⁵. In the 117 118 United States (US), NAFLD prevalence is projected to reach 33.5% among the adult population by 2030, due in large part to rising rates of obesity and other cardiometabolic risk factors⁶. 119 120 NAFLD is defined by ≥5% fat accumulation in the liver (hepatic steatosis) in the absence of other 121 known causes for liver disease, based on liver biopsy and/or non-invasive radiologic imaging^{3,4}. 122 The clinical spectrum of NAFLD ranges from bland steatosis to nonalcoholic steatohepatitis 123 (NASH) involving inflammation and hepatocellular ballooning injury with progressive fibrosis. At 124 least 20% of patients with NAFLD develop NASH with increased risk of consequent cirrhosis and primary liver cancer^{5,6}. To date, there is no licensed drug approved to treat NAFLD and prevent 125 126 its progression, and the general therapeutic approach focuses on improving the underlying 127 metabolic disorders such as glucose control and promotion of weight loss.

128 Individual susceptibility to NAFLD involves both genetic and environmental risk factors. 129 Current estimates of NAFLD heritability range from 20% to 50%⁷ while risk factors for NAFLD 130 include obesity (in particular, abdominal adiposity), insulin resistance and several features of 131 metabolic syndrome^{2,5,6,8}. Several genetic variants that promote the full spectrum of fatty liver 132 disease have been identified in genome-wide association studies (GWAS) utilizing cohorts 133 based on liver biopsy, imaging, and/or isolated liver enzyme values⁹⁻²². The most prominent 134 variants include p.1148M in *PNPLA3* and p.E167K in *TM6SF2*, which increase NAFLD risk, and a

6

loss-of-function variant in *HSD17B13* that confers protection against NASH¹⁶. However, the
limited number of genetic associations in NAFLD contrasts with other cardiometabolic disorders
where hundreds of loci have been mapped to date, such as obesity^{23,24}, type 2 diabetes²⁵,
hypertension²⁶, and plasma lipids²⁷. This highlights the need for expanded discovery with larger
samples and greater population diversity, with further integration of functional genomics data
sets to potentially identify the effector genes²⁸.

141 The Million Veteran Program (MVP) is among the world's largest and most ancestrally diverse biobanks²⁹. The availability of comprehensive, longitudinally collected Veterans Health 142 143 Administration (VA) electronic health records for US Veteran participants in the MVP also 144 makes it a promising resource for precision medicine. However, NAFLD is markedly 145 underdiagnosed clinically due to the invasive nature of the liver biopsy procedure, variable use 146 of imaging modalities and poor sensitivity of international diagnostic codes (ICD) for NAFLD^{4,30}. 147 The use of chronic elevation of serum alanine aminotransferase levels (cALT) as a proxy for 148 NAFLD was shown to improve specificity and positive predictive value in the NAFLD diagnostic algorithm within the VA Corporate Data Warehouse³¹. Accordingly, we recently adapted and 149 150 validated a cALT-based proxy NAFLD phenotype to facilitate case identification in MVP^{21} , 151 applying a rigorous exclusion of other conditions that are known to increase liver enzymes (e.g., 152 viral hepatitis, alcoholic liver disease, autoimmune liver disease, and known hereditary liver 153 disease). Moreover, we showed that our cALT-based proxy NAFLD phenotype had a sensitivity 154 of 80%, a specificity of 89%, an accuracy of 85%, a positive predictive value of 89%, and an area-155 under-the-curve of 87% compared to gold standard abdominal imaging, liver biopsy, and clinical 156 notes in a well-characterized sample of 178 patients in the VA healthcare system. In the current

7

157 study, we applied this cALT-based proxy NAFLD phenotype in MVP participants of 4 ancestral 158 groups³², and identified 90,408 NAFLD cases and 128,187 controls (Figure 1, and 159 Supplementary Figure 1).

Our aims are to: (i) perform a trans-ancestry genetic susceptibility analysis of the cALTbased proxy NAFLD phenotype in MVP; (ii) replicate the lead SNPs in external NAFLD cohorts with hepatic fat defined by liver histology or radiologic imaging; (iii) identify putative causal genes at the lead loci by using an ensemble "variant-to-gene" mapping method that integrates results from coding and functional genomic annotations, and quatitative trait loci (QTL); and (iv) identify each lead locus's genetic architecture by characterizing it's phenotypic association profile using data from the GWAS catalog, MVP LabWAS, and MRC IEU OpenGWAS database.

167

168 **Results**

169 An ancestry-diverse study population with a high prevalence of cardiometabolic traits

170 Our study consisted of 90,408 cALT cases and 128,187 controls comprising four ancestral 171 groups, namely European Americans (EA, 75.1%), African Americans (AA, 17.1%), Hispanic-172 Americans (HISP, 6.9%), and Asian-Americans (ASN, 0.9%, Supplemental Table 1. 173 **Supplemental Figure 1**). Consistent with the US Veteran population, MVP cases and controls 174 $(n\mathbb{Z}=218,595)$ were predominantly male (92.3%) with an average age of 64 years at study 175 enrollment (**Supplemental Table 1**). The prevalence of cirrhosis and advanced fibrosis in the 176 cALT cases ranged from 4.7% to 9.1%. With the exclusion of other known causes of liver disease as described previously²¹, cases were enriched for metabolic disorders (type 2 diabetes, 177

8

178 hypertension, and dyslipidemia), suggesting a link between chronic ALT elevation and metabolic179 risk factors.

180

181 Identification of trans-ancestry and ancestry-specific cALT-associated loci in MVP

182 To identify genetic loci associated with cALT, we performed trans-ancestry genome-wide scan 183 by meta-analyzing summary statistics derived from each individual ancestry (Methods and 184 Figure 1). In the trans-ancestry scan, 77 independent sentinel SNPs met conventional genomewide significance (P < 5×10^{-8}), of which 60 SNPs exceeded trans-ancestry genome-wide 185 186 significance ($P < 5x10^{-9}$). Of the 77 SNPs, 52 were previously reported to be associated with ALT, 187 including 9 that were also associated with NAFLD (i.e., PNPLA3, TM6SF2, HSD17B13, PPP1R3B, MTARC1, ERLIN1, APOE, GPAM, and SLC30A10;LYPLAL1; Figure 2 and Supplemental Table 2)⁹⁻ 188 12,14,16-22,33-35. Of the 25 newly identified loci, 14 were novel (IL1RN, P2RX7, CASP8, MERTK, 189 190 TRPS1, OGFRL1, HLA, SMARCD2;DDX42, CRIM1, FLT1, DNAJC22, HKDC1, UHRF2, STAP2;MPND), 191 whereas 11 have been associated with gamma-glutamyl transferase (GGT) and/or alkaline 192 phosphatase (ALP) levels³⁵.

In the ancestry-specific analyses, 55 loci in EAs, eight loci in AAs, and three in HISPs exceeded conventional genome-wide significance ($P < 5x10^{-8}$, **Supplemental Tables 3-5** and **Supplemental Figures 2-4**), of which 1 EA SNP and 2 AA SNPs were not captured in the transancestry analysis. No variants among ASN subjects achieved genome-wide significance, likely due to limited sample size (**Supplemental Figure 5**). Notably, the top two SNPs in the AA-only scan (with the genes *GPT* and *ABCB4* nearby each SNP, respectively) showed stronger

9

associations than observed for *PNPLA3*. These two SNPs are polymorphic among AA's but
nearly monomorphic in all other populations.

201

202 Replication of cALT-associated loci in liver biopsy and radiologic imaging data

203 To validate that our cALT-associated SNPs capture genetic susceptibility to NAFLD, we 204 assembled two external NAFLD cohorts, namely: (i) a Liver Biopsy Cohort consisting of 7,397 205 histologically characterized NAFLD cases and 56,785 population controls from various clinical 206 studies (Supplemental Table 6-7), and (ii) a Liver Imaging Cohort consisting of 44,289 207 participants with available radiologic liver imaging data and quantitative hepatic fat (qHF) 208 measurements (**Supplemental Table 8**). For each cohort, we performed a trans-ancestry lookup 209 of the 77 lead SNPs (Methods). In the Liver Biopsy Cohort, there was directional concordance 210 between effect estimates of biopsy-defined NAFLD in 66 of 77 SNPs (86%), including 15 SNPs 211 with a significant association (adjusted Bonferroni nominal $P < 6.5 \times 10^{-4}$), of which 8 have not been reported in genome- or exome-wide association studies previously (e.g., TRIB1, MTTP, 212 APOH, IFI30, COBLL1, SERPINA1, IL1RN, and FTO)(Supplemental Table 7)¹². In the Liver Imaging 213 214 Cohort, there was directional concordance between effect estimates of gHF in 49 of 77 SNPs 215 (64%). Among these, 11 were significantly associated with qHF (adjusted Bonferroni nominal P 216 < 6.5x10⁻⁴, Supplemental Table 8) of which 6 were novel (e.g., TRIB1, MTTP, APOH, IFI30, 217 COBLL1, and PPARG). As observed in previous studies owing to its role in glycogen storage (and 218 associated impact on imaging), the PPP1R3B locus was significantly associated with gHF, 219 however in the opposite direction from cALT, and not associated with biopsy-proven NAFLD^{12,36}. Collectively, 17 of 77 SNPs were validated in external histologic and/or radiologic 220

10

221 NAFLD, of which 9 were previously unreported, namely five in both biopsy and imaging cohorts 222 (*TRIB1, MTTP, APOH, IFI30,* and *COBLL1*), three in biopsy cohort alone (*FTO, SERPINA1,* and 223 *IL1RN*) and one in imaging cohort with a nominal significance in biopsy cohort (*PPARG*) 224 (**Supplemental Table 1**). An additional 24 SNPs were nominally associated (P < 0.05) with 225 directional concordance with histological and/or radiologic hepatic fat.

226

227 Genomic risk scores and histologically characterized NAFLD

228 We next constructed genetic risk scores (GRSs) based on effect estiamtes from our cALT GWAS 229 SNPs in 4 independent liver biopsy cohorts to quantify the cumulative predictive power of our 230 77 sentinel variants (Supplemental Table 9, Supplemental Figure 8). A 77 SNP-based GRS was predictive of NAFLD in the meta-analyzed liver biopsy cohorts (GRS-77, P = 3.7×10^{-28}). 231 232 Stratification of GRS-77 into a GRS consisting of a set of 7 well-established NAFLD SNPs (GRS-7), 233 and a GRS consisting of 70 remaining SNPs (GRS-70) revealed significant independent capacity to predict histologically characterized NAFLD (GRS-7, P = 1.7×10^{-13} ; GRS-70, P = 1.7×10^{-5}), 234 235 further supporting the clinical relevance of our panel of SNPs derived from proxy NAFLD 236 phenotype.

237

238 cALT heritability and genetic correlations with other phenotypes

To further characterize the architecture of our cALT phenotype and its relationship with other traits, we estimated heritability and genetic correlations with other traits using linkage disequilirium (LD) score regression³⁷⁻³⁹ (**Methods**). The SNP-based liability-scaled heritability was estimated at 16% (95% CI: 12-19, P < 1×10^{-6}) in EA. Genetic correlation analysis between

11

243 NAFLD from the EA-only scan and 774 complex traits from LD Hub (Methods) identified a total of 116 significant associations (adjusted Bonferroni nominal $P < 6.5 \times 10^{-5}$, Supplemental Table 244 245 **10**). These encompassed 78 cardiometabolic risk factors (67.2%) including measures of obesity 246 and adiposity, type 2 diabetes, hypertension, dyslipidemia, and coronary artery disease, which is consistent with reports from observational studies correlating these traits to NAFLD⁴⁰. 247 248 Additional genetically correlated traits represented general health conditions (11.2%), 249 educational attainment and/or socio-economic status (12.0%) and other conditions such as 250 gastro-oesophageal reflux, osteoarthritis, gout, alcohol intake, smoking, ovary removal, and 251 urinary albumin-to-creatinine ratio (9.5%).

252

253 Identification of conditionally independent cALT-associated variants

254 To discover additional conditionally independent cALT signals within the 77 genomic regions, 255 we performed a formal conditional analysis using stepwise regression on individual level data 256 for all single-ancestry sentinel variants (namely 51 EA, 8 AA, and 3 HISP genomic regions). We 257 detected a total of 29 conditionally independent SNPs ($P < 1x10^{-5}$) flanking five known and 16 258 novel cALT loci in EA (Supplemental Table 11). In particular, the GPT locus showed the highest 259 degree of regional complexity with 4 conditionally independent SNPs, followed by AKNA with 3 260 conditionally independent SNPs. For one novel locus located on chromosome 12 between 121-261 122Mb, the trans-ancestry lead variant (rs1626329) was located in P2RX7, whereas the lead 262 peak variant for EA mapped to HNF1A (rs1169292, Figure 3). Both variants are in strong LD 263 with distinct coding variants (P2RX7: rs1718119, Ala348Thr; HNF1A: rs1169288, lle27Leu) and 264 are compelling candidate genes for metabolic liver disease. In AA, we observed a total of six

12

conditionally independent variants at three genomic regions, namely three variants at *GPT*, two
 at *AKNA* and one at the *ABCB4* locus (**Supplemental Table 11**). No conditionally independent
 variants were identified in Hispanics. Collectively, 35 additional variants were identified at 22
 loci across multiple ancestries by formal conditional analysis.

269

270 Fine mapping to define potential causal variants in 95% credible sets

To leverage the increased sample size and population diversity to improve fine-mapping 271 272 resolution, we computed statistically derived 95% credible sets using Wakefield's approximate Baves' factors⁴¹ using the trans-ancestry, EA, AA, and HISP summary statistics (Supplemental 273 274 **Table 12-15.** Methods. Trans-ancestry fine-mapping reduced the median 95% credible set size 275 from 9 in EA (with IQR 3 - 17) to 7.5 variants (IQR 2 - 13). A total of 11 distinct cALT associations 276 (e.g. MTARC1, IL1RN, OGFRL1, PPP1R3B, SOX7;RP1L1;C8orf74, TRIB1, ERLIN1, TRIM5, 277 OSGIN1;MLYCD, TM6SF2 and PNPLA3) were resolved to a single SNP in the trans-ancestry meta-278 regression, with an 4 additional loci suggesting single SNP sets from EA (n=2) and AA (n=2) 279 ancestry-specific scans.

280

281 Liver-specific enrichment of cALT heritability

To ascertain the tissues contributing to the disease-association underlying cALT heritability, we performed tissue-specific heritability analysis using stratified LD score regression. The strongest associations were observed for genomic annotations surveyed in liver, hepatocytes, adipose, and immune cell types among others (e.g., liver histone H3K36me3 and H3K4me1, adipose nuclei H3K27ac, spleen TCRy\delta, eosinophils in visceral fat; P < 0.001, **Supplemental Table 16**).

13

287 Medical subject heading (MeSH)-based analysis showed enrichment mainly in hepatocytes and 288 liver (False Discovery Rate (FDR) < 5%, Supplemental Table 17). Gene set analysis showed strongest associations for liver and lipid-related traits (P-value $< 1 \times 10^{-6}$, Supplemental Table 289 290 **18**). Enrichment analyses using publicly-available epigenomic data implemented in GREGOR 291 enrichment analysis (Methods) showed that most significant enrichments were observed for 292 active enhancer chromatin state in liver, epigenetic modification of histone H3 in hepatocytes 293 or liver-derived HepG2 cells (e.g. H3K27Ac, H3K9ac, H3K4me1, H3K4me3; adjusted Bonferroni nominal P < 1.8×10^{-5} , Supplemental Table 19 and 20). These analyses additionally support the 294 295 hypothesis that our cALT GWAS captures multiple physiological mechanisms that contribute to 296 NAFLD heritability. Furthermore, DEPICT-based predicted gene function nominated 28 gene 297 candidates, including the known genes PNPLA3 and ERLIN1 (FDR <5%, Supplemental Table 21), 298 as well as well-known cardiometabolic disease genes such as PPARG.

299

300 Coding variants in putative causal genes driving cALT associations

301 There were six novel trans-ancestry loci for which the lead SNP is a coding missense variant 302 (Supplementary Table 22), namely Thr1412Asn in CPS1, Glu430Gln in GPT, Val112Phe in TRIM5, 303 Ala163Thr in DNAJC22, Glu366Lys in SERPINA1 and Cys325Gly in APOH. To identify additional 304 coding variants that may drive the association between the lead SNPs and cALT risk, we 305 investigated predicted loss of function (pLoF) and missense variants in high LD to the identified 306 cALT lead variants ($r^2 > 0.7$ in each respective 1000 Genomes super-population, **Supplemental** 307 Table 22). Four previously described missense variants were replicated in the current study, 308 including Thr165Ala in MTARC1, lle291Val in ERLIN1, Glu167Lys in TM6SF2 and lle148Met in

14

309 PNPLA3. Among novel loci, missense variants in high LD with lead variants included the genes 310 CCDC18, MERTK, APOL3, PPARG, MTTP, MLXIPL, ABCB4, AKNA, GPAM, SH2B3, P2RX7, NYNRIN, 311 ANPEP, IFI30 and MPV17L2. Among the trans-ancestry coding missense variants, eleven were 312 predicted based on two methods (SIFT, PolyPhen-2) to have potentially deleterious and/or damaging effects in protein function (Supplementary Table 22)^{42,43}. An AA-specific locus on 313 314 chromosome (rs115038698, chr7:87024718) was in high LD to a nearby missense variant Ala934Thr in ABCB4 (rs61730509, AFR r²=0.92) with a predicted deleterious effect, where the T-315 allele confers an increased risk of cALT (β =0.617, P=1.8x10⁻²⁰). In summary, among our 77 trans-316 317 ancestry loci, 24 prioritized a candidate gene based on a missense variant in high LD with the 318 lead SNP, including 5 novel loci with external validation (e.g., SERPINA1, APOH, PPARG, MTTP 319 and IFI30;MPV17L2).

320

321 Additional approaches to nominating putative causal genes

322 Co-localization analyses: We performed colocalization analyses with gene expression and 323 splicing across 48 tissues measured by the GTEx project, and overlapped our lead SNPs with 324 histone quantitative trait locus (QTL) data from primary liver to identify cALT-associated 325 variants that are also associated with change in gene expression (eQTLs), splice isoforms 326 (sQTLs), or histone modifications (hQTLs, Methods, Supplemental Table 23). Across all tissues, 327 a total of 123 genes were prioritized, including 20 genes expressed in liver tissue (Methods). 328 For liver tissue alone, a total of eight variant-gene pairs were identified where the allele 329 associated with protection against cALT was also associated with reduced transcription levels. 330 Furthermore, sQTL analysis in GTEx v8 identified two genes in the liver (HSD17B13 and ANPEP)

15

331 and 13 genes that were affected in at least two tissues (Supplemental Table 24). Finally, two of our lead SNPs were in high LD ($r^2 > 0.8$) with variants that regulated H3K27ac levels in liver 332 333 tissue (hQTLs), namely EFHD1 (hQTL SNPs rs2140773, rs7604422 in EFHD1) and FADS2 loci (hQTL rs174566 in FADS2)⁴⁴. 334 335 Assay for chromatin accessibility using liver-derived cells: We next mapped our cALT loci to 336 regions of open chromatin using ATAC-seg in three biologically-relevant liver-derived tissues 337 (human liver, liver cancer cell line [HepG2], and hepatocyte-like cells [HLC] derived from pluripotent stem cells)⁴⁵. Additionally, we used promoter-focused Capture-C data to identify 338 339 those credible sets that physically interact with genes in two relevant cell types (HepG2 and 340 liver). For each credible set, we identified genes with significant interactions (CHiCAGO score > 341 5, Methods) that overlap with at least one lead variant (Supplemental Table 25). These 342 datasets are useful entry points for deciphering regulatory mechanisms involved in the 343 pathophysiology of NAFLD. Based on DEPICT gene prediction, coding variant linkage analysis, 344 and QTL colocalization (Supplemental Tables 18-25), 215 potentially relevant genes were 345 identified for the 77 loci. A protein-protein interaction (PPI) analysis revealed that among the 346 192 available proteins, 86 nodes were observed, with strong PPI enrichment (P < 9.0×10^{-8}) 347 indicating that the protein network shows substantially more interactions than expected by 348 chance (Supplemental Table 26 and Supplemental Figure 6).

349

350 Variant-to-Gene Ensembl Mapping Approach to nominate putative causal genes

351 We developed an ensemble method for predicting the likely causal effector gene at 77 loci 352 based on 8 distinct gene-mapping analyses, including: SNP-gene overlap, DEPICT gene

16

353 prediction, coding variant linkage, colocalization with eQTL, sQTL and hQTL, promotor Capture-354 C and/or ATAC-Seq peak overlap, and PPI network analysis. For each gene that resides in a 355 sentinel locus, the number of times that it was identified in the eight analyses was summarized 356 into a nomination score which reflects the cumulative evidence that the respective gene is the 357 causal effector gene in the region. This ensemble method for mapping variants to genes 358 resulted in the nomination of a single gene as the causal effector gene at 53 of 77 genomic loci. 359 At the remaining 24 loci, two loci lacked any data to support the nomination of a causal gene, 360 and at 22 loci two or more causal genes were nominated because they shared the maximum 361 nomination score (Supplemental Table 27). We highlighted 35 loci for which a causal gene was 362 prioritized by at least 3 sources of evidence (or 4 sources of evidence for coding variants) in 363 Table 1. These included 6 loci with co-localizing eQTLs in liver or adipose tissues and connection 364 to the predicted gene via Promoter CaptureC data (i.e., EPHA2, IL1RN, SHROOM3, HKDC1, 365 PANX1, DHODH;HP).

366 <u>Gene expression of nominated genes in the Liver Single Cell Atlas:</u> To confirm that the 367 nominated genes are involved in liver biology, we performed a gene expression lookup in single 368 cell RNA-Seq data from the Liver Single Cell Atlas⁴⁶. As a result, for 76 of 77 loci a gene was 369 nominated that was expressed in at least one liver cell type, with exception of the rs9668670 370 locus which nominated several keratin genes (*KRT84;KRT82;KRT74*)(**Supplemental Table 23**).

371

Transcription factor analysis

We observed that 14 nominated genes are transcription factors (TF) (Supplemental Table 28).
Using the DoRothEA data in OmniPath we identified that two of these TFs have several

17

downstream target genes that were also identified in our GWAS scan (Methods). Notably, the
CEBPA TF targets the downstream genes *PPARG*, *TRIB1*, *GPAM*, *FTO*, *IRS1*, *CRIM1*, *HP*, *TBC1D8*,
and *CPS1*, but also *NCEH1*, a gene in the vicinity of one of our associations that lacked a
nominated candidate gene. Similarly, HNF1A, the lead gene in the EA scan (and corresponding
to the trans-ancestry *P2RX7* locus) targets *SLC2A2*, *MTTP*, and *APOH*.

380

381 Pleiotropy and related-trait genetic architecture of lead cALT SNPs

382 We next sought to identify additional traits that were associated with our 77 trans-ancestry 383 lead SNPs using four different approaches. First, a LabWAS of distinct clinical laboratory test 384 results⁴⁷ in MVP (**Methods**) yielded 304 significant SNP-trait associations (adjusted Bonferroni 385 nominal P = 3.1×10^{-5} , Supplemental Table 29, Supplemental Figure 7). Second, a PheWAS 386 Analysis in UK Biobank data using SAIGE (Methods) identified various SNP-trait associations 387 that mapped to loci previously associated with liver and cardiometabolic traits, as well as 388 additional enriched association for gallstones, gout, arthritis, and hernias (adjusted Bonferroni 389 nominal $P < 4.6 \times 10^{-7}$, Supplemental Table 30). In particular, we examined all associations for 390 PheCode 571.5, "Other chronic nonalcoholic liver disease" which comprised 1,664 cases and 391 400,055 controls, which with a disease prevalence of 0.4% seems to be underreported. Still, of 392 the 73 variants with available data, 14 were both nominally associated and directionally consistent with our scan (signed binomial test $P=3.4 \times 10^{-9}$), providing additional validation for 393 394 our scan (Supplementary Table 31). Third, a SNP lookup using the curated data in the MRC IEU 395 OpenGWAS project (Supplemental Table 32) identified 2,892 genome-wide significant SNP-trait 396 associations for trans-ancestry SNPs, with additional 283 SNP-trait associations for the ancestry-

18

397 specific lead SNPs. Finally, we performed cross-trait regional colocalization analyses of EA, AA,
398 and HISP lead loci with 36 other GWAS statistics of cardiometabolic and blood cell related traits
399 (Methods). This resulted in significant regional colocalization for 64 SNP-trait pairs in EA, 32
400 SNP-trait pairs in AA, and 12 SNP trait pairs in HISP (Supplemental Table 33).

401 Based on the four analyses described above, we selected all SNP-trait associations 402 relevant phenotypes to NAFLD biology and classified them as liver (e.g. ALT, ALP, AST, and GGT), 403 metabolic (e.g. HDL, LDL, and total cholesterol, triglycerides, BMI, glucose, and HbA1c), or 404 inflammatory traits (e.g., C-reactive protein, white blood cell count, lymphocyte count, 405 granulocytes, neutrophils, monocyte count, basophils, eosinophils, and myeloid white cells) 406 (Supplemental Tables 29-33, Figure 4). Across the trans-ancestry lead variants (n=77), ancestry-407 specific (n=3), and secondary proximal associations (HNF1A, n=1), 17 SNPs showed association 408 with only liver traits (Figure 4). In contrast, 20 loci showed associations with both liver and 409 metabolic traits whereas 5 loci (IL1RN, TMEM147;ATP4A and RORA) showed associations with 410 both liver and inflammatory traits. Finally, 38 loci showed association with all three traits: liver 411 enzymes, cardiometabolic risk, and inflammation, including 14/17 loci that were externally 412 validated in Liver Biopsy and/or Imaging Cohorts (color-coded in red in Figure 4). Collectively, 413 our findings identify novel cALT-associated genetic loci with pleotropic effects that may impact 414 hepatic, metabolic and inflammatory traits.

415

416 **Discussion**

417 In this study, we describe the first of its kind multi-ancestry GWAS of cALT-based NAFLD, which 418 resulted in a total of 77 trans-ancestry loci, of which 25 have not been associated with NAFLD

19

419 or ALT before. We additionally identified three ancestry-specific loci, as well as 29 conditionally 420 independent SNPs in EAs and six in AAs. We assembled two external replication cohorts with 421 histologically confirmed NAFLD (7,397 NAFLD cases and 56,785 population controls) and 422 hepatic fat defined by imaging (n = 44,289), and validated the association of 17 SNPs with 423 NAFLD, of which nine are novel (*TRIB1, PPARG, MTTP, SERPINA1, FTO, IL1RN, COBLL1, APOH,* 424 and *IFI30*). Furthermore, a GRS based on novel SNPs alone was predictive of histologically 425 defined NAFLD.

Pleiotropy analysis allowed us to characterize the genetic architecture of NAFLD and 426 427 remarkably, all validated SNPs showed significant associations with metabolic risk factors 428 and/or inflammatory traits, the most common being plasma lipid-related, followed by glycemic 429 traits, hypertension, and cardiovascular disease. Our ensemble variant-to-gene mapping 430 method nominated a single causal effector gene at 53 genomic loci. We found that these genes 431 were highly expressed in one or more cell types in the liver and have prior biological 432 connections to liver metabolism, physiology, or disease, making this list compelling for further 433 interrogation. Collectively, our findings offer a comprehensive, expanded, and refined view of 434 the genetic contribution to cALT-based NAFLD with potential clinical, pathogenic, and 435 therapeutic relevance.

Our proxy NAFLD phenotype was based on chronic ALT elevation with the exclusion of other known diagnoses of liver disease or causes of ALT elevation (e.g. viral hepatitis, alcoholic liver disease, hemochromatosis), based on previous validation within VA population ^{21,31}. In this regard, several GWAS studies of liver enzyme levels have been reported, particularly of serum ALT^{10,11,16,34,35}, but not all studies systematically excluded other causes of ALT elevation. For

20

441 example, Pazoki et al recently reported 230 locis related to ALT, of which 52 were also included in our panel of 77 (67.5%) lead cALT loci^{34,35}. While our cALT approach was designed to enhance 442 the specifity of non-invasive NAFLD diagnosis ^{21,31}, this overlap is not surprising given the high 443 444 prevalence of NAFLD in the general population. Furthermore, we noted that inflammatory traits 445 were associated with over half of the cALT-based NAFLD loci in our study. Indeed, while ALT can 446 be normal in persons with hepatic steatosis, we focused on chronic ALT elevation that 447 represents ongoing hepatocellular injury that can promote liver disease progression. For our 448 controls, we excluded individuals with mild ALT elevation and selected healthier 'super-449 controls' to minimize potential phenotype misclassification (e.g. attributing cases as controls) 450 that can result in a bias towards the null.

451 The MVP is one of the world's largest and most ancestrally diverse biobanks, of which 452 25% of the participants are of non-European ancestry, and this diversity enhanced the value of 453 this study. Utilizing data from multiple ancestries allowed us to narrow down putative causal 454 variants for NAFLD through trans-ancestry fine-mapping. Moreover, we identified 2 cALT-based 455 NAFLD loci specifically in AAs. For example, the lead SNP at the ABCB4 locus (rs115038698) was 456 in high LD with the missense variant rs61730509 (Ala934Thr, AFR r^2 =0.92) and had a very potent effect (OR=1.87, CI=1.64-2.14, P=1.8x10²⁰). This variant is of low frequency in AA 457 458 (MAF=1.2%) but virtually absent in EA and ASN. ABCB4, also known as multidrug resistance 459 protein 3 (*MDR3*), is a compelling candidate gene, as it is involved in hepatocyte lipid transport 460 and has been previously implicated in cholestasis, gallbladder disease, and adult biliary fibrosis/cirrhosis⁴⁸⁻⁵⁰. 461

21

462 Ultimately, the affirmative external validation of our lead cALT-based NAFLD loci in 463 NAFLD cohorts with liver biopsies and imaging supports the relevance of our proxy phenotype for NAFLD. A total of 17 loci associated with cALT-based NAFLD were also significantly 464 465 associated with hepatic fat based on liver biopsy and/or radiological imaging. These included 466 loci previously associated with NAFLD or all-cause cirrhosis (e.g., PNPLA3, TM6SF2, HSD17B13, 467 MTARC1, ERLIN1, GPAM, and APOE), but also included several of the novel loci reported here 468 (e.g., TRIB1, SERPINA1, MTTP, IL1RN, IFI30, COBLL1, APOH, FTO, PPP1R3B and PPARG). For all 469 loci except PPP1R3B, we observed concordant directionality of effects between cALT and hepatic fat. The apparent discrepancy in the PPP1R3B locus has been reported before¹² and 470 471 may represent diffuse attenuation on radiologic images due to hepatic accumulation of glycogen^{36,51} rather than triglycerides⁵². These novel and validated genes make excellent gene 472 473 candidates for NAFLD.

A substantial fraction of our cALT-based NAFLD loci showed a shared genetic co-474 475 architecture with metabolic traits (Figure 4). Several genes and liver-enriched transcription 476 factors involved in LDL and triglyceride pathways have been indentified, such as the liver-biospy and/or imaging validated TRIB1, FTO^{53,54}, COBLL1^{55,56}, MTTP, TM6SF2, PPARG, APOE, and 477 GPAM⁵⁷⁻⁶⁰, but also the cALT-only associated variants in MLXIPL, MLXIP, CEBPA, FADS2, APOH, 478 479 RORA, and HNF1A. TRIB1 presumably regulates VLDL secretion by promoting the degradation 480 carbohydrate-response element binding protein (ChREBP, encoded by MLXIPL), reducing 481 hepatic lipogenesis and limiting triglyceride availability for apolipoprotein B (apoB) lipidation. 482 Furthermore, TRIB1 co-activates the transcription of MTTP, which encodes the microsomal 483 triglyceride transfer protein that loads lipids onto assembling VLDL particles and facilitates their

22

484 secretion by hepatocytes. Lomitapide, a small molecule inhibitor of MTTP, is approved as a treatment for lowering LDL cholesterol in homozygous familial hypercholesterolemia⁶¹ and a 485 486 potential therapeutic target for NAFLD. TRIB1 is also involved in the degradation of the key hepatocyte transcription factor, CCAAT/enhancer-binding protein alpha (CEBPA)⁶², which 487 488 together with HNF1A (HNF1 Homeobox A), $ROR\alpha$ (retinoic acid receptor-related orphan 489 receptor- α) and *MIR-122* are involved in a feedback loop of the the liver-enriched transcription factor network to control hepatocyte differentiation⁶³. ROR α is also a suppressor of 490 transcriptional activity of peroxisome proliferator-activated receptor y $(PPARy)^{64,65}$. *PPARG*. 491 492 encoding PPARy, upregulates LDL-receptor-related protein 1 (LRP1), which facilitates the hepatic uptake of triglyceride-rich lipoproteins via interaction with apolipoprotein E (apoE)^{66,67}. 493 494 PPARG is predominantly expressed in adipose tissue, and hepatic expression levels of PPARG are significantly increased in patients with NAFLD⁶⁸. Large randomized controlled clinical trials 495 496 have reported that the PPARG agonists rosiglitazone and pioglitazone improve NAFLD-related hepatic steatosis, hepatic inflammation, and fibrosis⁶⁹⁻⁷³. However, the treatment is frequently 497 498 accompanied with weight gain and fluid retention, limiting its application and potential long-499 term drug adherence. ROR α however, competes with PPARy for binding to PPARy target 500 promoters, and therapeutic strategies designed to modulate RORa activity in conjunction with PPARy may be beneficial for the treatment of NAFLD. ApoE and ApoH⁵⁷ play an important role 501 502 in the production and clearance of VLDL by facilitating the hepatic uptake of triglyceride-rich 503 lipoproteins⁷⁴⁻⁷⁷. ApoE deficiency is suggested to affect hepatic lipid deposition in dietarychallenged murine models⁷⁸. Similarly, a Western high-fat cholesterol-rich diet accelerates the 504 505 formation of NASH with fibrosis in ApoE-deficient mice⁷⁹.

23

506 More than half of our cALT-based NAFLD loci had a significant association with at least one inflammatory trait (Figure 4), consistent with the multiple-hit hypothesis of NAFLD⁸⁰. For 507 example, the transcription factor MafB regulates macrophage differentiation⁸¹ and genetic 508 509 variation in MAFB has been associated with hyperlipidemia and hypercholesterolemia²⁷. Mice more susceptible to 510 Mafb-deficiency are with macrophage-specific obesity and atherosclerosis^{82,83}. FADS1 and FADS2 are markedly induced during monocyte to macrophage 511 512 differentiation, and it is hypothesized that they impact metabolic disease by balancing proinflammatory and proresolving lipid mediators^{84,85}. Another interesting locus is *IL1RN*, which 513 514 in our study is associated with lower risk of cALT and liver-biopsy characterized NAFLD. GTEx 515 data shows heterogeneous directions of effect across various tissues, with the minor G-allele 516 being associated with increased *IL1RN* expression in liver but decreased expression in 517 subcutaneous adipose tissue. *IL1RN* encodes the anti-inflammatory cytokine interleukin-1 518 receptor antagonist (IL-1Ra) and is a natural inhibitor of IL-1 activity by blocking the binding of IL-1β to IL-1R, and is considered a potential therapeutic target for NAFLD treatment⁸⁶. IL-1β has 519 been shown to lead to chronic low-grade inflammation⁸⁷⁻⁸⁹, insulin resistance and hepatic fat, 520 and promotes hepatic steatosis, inflammation and fibrosis^{90,91}. A study in mice has shown that 521 IL-1R-deficiency protects from liver fibrosis⁹², and the deletion of IL-1R reduces liver injury in 522 acute liver disease by blocking IL-1 driven autoinflammation⁹³. In two studies of patients with 523 diabetes, blockade of IL-1 signaling with Anakinra (a recombinant form of IL-1Ra) improved 524 glycemic control⁹⁴⁻⁹⁶. It remains to be investigated whether remodeling of the adipose tissue 525 inflammasome via IL-1 signaling blockade in obesity-associated NAFLD offers potential 526 therapeutic benefit. Other loci implicated with inflammatory traits include RORA^{97,98}. IFI30^{99,100}. 527

24

528 *CD276*¹⁰¹⁻¹⁰³, *FCGR2A*¹⁰⁴, and *P2RX7*¹⁰⁵⁻¹⁰⁷. Interestingly, these inflammation-related genes and 529 pathways emerged from our cALT-based NAFLD GWAS despite the indirect assessment of our 530 phenotype, clearly implicating inflammation early in NAFLD.

531 Finally, PANX1 and MERTK genes that are associated with liver traits only seem 532 particulary interesting. For PANX1, the directional concordance of effects between cALT and 533 PANX1 gene expression in the liver suggests possible relevance as a therapeutic target. It has 534 been reported that the genetic deletion of Pannexin 1 (encoded by PANX1) has a protective effect in a mouse model of acute and chronic liver disease^{108,109}, and our data demonstrate that 535 536 a SNP near PANX1 was associated with reduced PANX1 expression and reduced risk of NAFLD. 537 These data nominate PANX1 as a therapeutic target for silencing in NAFLD treatment. For MerTK, two missense variants (Arg466Lys and ||e518Va|, $r^2=0.98$) were predicted to affect 538 539 protein function. MerTK signaling in hepatic macrophages was recently shown to mediate hepatic stellate cell activation and promote hepatic fibrosis progression¹¹⁰. Variants in *MERTK* 540 were associated with liver fibrosis progression in HCV-infected patients¹¹¹, raising the possibility 541 for MerTK as a novel therapeutic target against fibrosis¹¹². We emphasize that functional 542 543 studies of our nominated causal genes are needed to demonstrate casual relevance, their 544 impact on hepatosteatosis, and ultimately to determine their underlying mechanisms.

545 In conclusion, we discovered 77 genomic loci associated with cALT-based NAFLD in a 546 large, ancestrally diverse cohort. Our cases of cALT-based NAFLD were excluded for other 547 known causes of liver disease or elevated ALT and, not surprisingly, were substantially enriched 548 for metabolic disorders. We replicated our findings in external cohorts with hepatic fat defined 549 by liver biopsy or radiologic imaging. The genetic architecture of the lead loci indicate a

- predominant involvement of metabolic and inflammatory pathways. This study constitutes a much-needed large-scale, multi-ancestry genetic resource that can be used to build genetic prediction models, identify causal mechanisms, and understand biological pathways contributing to NAFLD initiation and disease progression.
- 554

26

SNP	Position	Gene	AA-Change	SIFT/PP2 [*]	e/sQTL ^{**}	Other †	Pleiotropy [‡]
rs6541349	1:93787867	CCDC18	p.Leu1134Val	+/-	+		М
rs2642438	1:220970028	MTARC1	p.Thr165Ala	-/-	+ (A)	+	М
rs11683409	2:112770134	MERTK	p.Arg466Lys	-/-		++	
rs17036160	3:12329783	PPARG	p.Pro12Ala	-/-	+	++	Μ
rs17598226	4:100496891	MTTP	p.lle128Thr	-/-	+	+	
rs115038698	7:87024718	ABCB4	p.Ala934Thr	+/+	+	+	M,I
rs799165	7:73052057	MLXIPL	p.Gln241His	-/+	+	+	M,I
			p.Ala358Val	-/-	+	+	M,I
rs7041363	9:117146043	AKNA	p.Pro624Leu	+/-	+	+	М
rs10883451	10:101924418	ERLIN1	p.lle291Val	-/-		++	М
rs4918722	10:113947040	GPAM	p.lle43Val	-/-	+	++	М
rs11601507	11:5701074	TRIM5	p.Val112Phe	-/-		++	M,I
rs1626329	12:121622023	P2RX7	p.Ala348Thr	-/-	+	+	
rs11621792	14:24871926	NYNRIN	p.Ala978Thr	-/-	+ (L,A)	+	M,I
rs28929474	14:94844947	SERPINA1	p.Glu366Lys	-/+		+++	M,I
rs7168849	15:90346227	ANPEP	p.Ala311Val	-/-	+ (L)	+	
rs1801689	17:64210580	APOH	p.Cys325Gly	+/+		++	M,I
rs132665	22:36564170	APOL3	p.Ser39Arg	-/-	+ (A)	+	
rs738408	22:44324730	PNPLA3	p.lle148Met	+/+		+++	M,I

555 Table 1a. Gene nominations at loci with strongest evidence for coding variants.

556 Genes nominated with various sources of evidence are listed as follows.

^{*}Prio to the slash symbol: '+' indicates 'deleterious' in SIFT and '-' otherwise. After slash symbol: '+'

558 denotes probably damaging in Polyphen-2 and '-' otherwise.

^{**} The '+' indicates colocalization between NAFLD GWAS variant and GTEx QTL varint (COLOC

560 PP4/(PP3+PP4) > 0.9). (L) denotes QTL effect in Liver, (A) denotes QTL in Adipose.

561 *Each '+' represent evidence from DEPICT, PPI data, or if the lead SNP is within the transcript; coding
 562 variants also include '+' from hQTLs/Capture-C evidence.

563 ‡Pleiotropy is limited to association with Metabolic (M) or Inflammatory (I) Traits

564

27

SNP	Position	Gene	hQTL	CaptureC	e/sQTL ^{**}	Other †	Pleiotropy [‡]
rs36086195	1:16510894	EPHA2		+	+ (L,A)	+	М
rs6734238	2:113841030	IL1RN		+	+ (A)	++	I
rs10201587	2:202202791	CASP8		+	+	+	М
rs11683367	2:233510011	EFHD1	+		+ (L)	+	
rs61791108	3:170732742	SLC2A2		+		+++	М
rs7653249	3:136005792	РССВ			+	++	M,I
rs12500824	4:77416627	SHROOM3		+	+ (L)	+	М
rs10433937	4:88230100	HSD17B13			+ (L,A)	+	M,I
rs799165	7:73052057	BCL7B		+	+	+	M,I
rs687621	9:136137065	ABO			+	+	M,I
rs35199395	10:70983936	HKDC1		+	+ (L,A)	+	М
rs174535	11:61551356	FADS2	+		+ (A)	++	M,I
rs56175344	11:93864393	PANX1			+ (L,A)	++	
rs34123446	12:122511238	MLXIP		+	+	+	M,I
rs12149380	16:72043546	DHODH		+	+	+	M,I
		НР		+	+ (A)		M,I
rs2727324	17:61922102	DDX42		+	+	+	М
		SMARCD2			+	+	М
rs5117	19:45418790	APOC1			+	++	M,I

566 **Table 1b. Gene nominations at loci with strongest evidence for non-coding variants.**

567 Genes nominated with various sources of evidence are listed as follows.

^{*}Prio to the slash symbol: '+' indicates 'deleterious' in SIFT and '-' otherwise. After slash symbol: '+'

569 denotes probably damaging in Polyphen-2 and '-' otherwise.

^{**} The '+' indicates colocalization between NAFLD GWAS variant and GTEx QTL varint (COLOC

571 PP4/(PP3+PP4) > 0.9). (L) denotes QTL effect in Liver, (A) denotes QTL in Adipose.

572 *Each '+' represent evidence from DEPICT, PPI data, or if the lead SNP is within the transcript; coding
 573 variants also include '+' from hQTLs/Capture-C evidence.

574 ‡Pleiotropy is limited to association with Metabolic (M) or Inflammatory (I) Traits

575

576

577





29

581 The flow diagram shows in the red box our study design with initial inclusion of 430,400 Million Veteran Program 582 participants with genotyping and ancestry classification by HARE, exclusion of individuals with known liver disease 583 or alcohol dependence and inclusion of subjects based on chronic ALT elevation (case) or normal ALT (control). 584 This resulted in 90,408 NAFLD cases and 128,187 controls with EA, AA, HISP and ASN ancestries that were 585 examined in primary trans-ancestry and ancestry-specific genome-wide association scans. The orange box of the 586 flow diagram highlights our results of trans-ancestry and ancestry-specific meta-analyses identifying 77 trans-587 ancestry loci + 1 EA-specific + 2 AA-specific loci that met genome-wide significance. The green box summarizes the 588 results from external replication cohorts, whereas the blue box indicates all the post-GWAS annotation analyses 589 that we performed, which include secondary signal analysis, fine-mapping (95% credible sets), (tissue-specific) 590 heritability estimation, genetic correlations analysis, variant-to-gene mapping and pleiotropy analysis. 591

593 Figure 2. Manhattan plot of NAFLD GWAS of 90,408 NAFLD and 128, 187 controls in trans-

594 ancestry meta-analysis.





596	Nominated genes are indicated for 77 loci reaching genome-wide significance (P<5x10 ⁻⁸).
597	Previously reported NAFLD-loci with genome-wide significant association are indicated in green
598	font. The red stars indicate the SNPs that have been validated with liver biopsy and/or
599	radiologic imaging.
600	

602 Figure 3. Chromosome 12 locus points to different genes in trans-ancestry (right) and



603 European-only (left) analyses.



The lead variants in each analysis are highlighted (trans-ethnic on the right, european on the left). The trans-ethnic peak concerns rs1626329 in P2RX7, whereas rs1169292 was identified in European-only analysis and covers HNF1A. The r² between the two lead SNPs in < 0.01 in any of the 1000 Genomes super-populations.

609

611 Figure 4. Venn diagram depicting overlapping liver, metabolic and inflammatory traits among

612 NAFLD-associated loci.



613

Overlapping liver (blackblack), metabolic (purplepurple) and/or inflammatory (green) traits are shown in association with 77 trans-ancestry and additional ancestry-specific lead SNPs. The trait categorizations reflect significant SNP-trait associations identified by: 1) LabWAS of clinical laboratory results in MVP; 2) PheWAS with UKBB data using SAIGE; 3) SNP lookup using the curated data in the IEU OpenGWAS projects; and 4) cross-trait colocalization analyses using COLOC of EA, AA and HISP lead loci with 36 other GWAS statistics of cardiometabolic and blood cell related traits. GenesGenes denoted in bold and color-coded in red refer to the loci also

621	associated with quantitative hepatic fat on imaging analyses or histologically characterized
622	NAFLD from liver biopsies. * Locus identified in European-only GWAS. ** Locus identified in
623	African American-restricted analysis. *Secondary signal from European analysis (e.g.
624	HNF1A/P2RX7).
625	

627 References

628 Asrani, S.K., Devarbhavi, H., Eaton, J. & Kamath, P.S. Burden of liver diseases in the world. J 1. 629 Hepatol 70, 151-171 (2019). 630 2. Younossi, Z., Anstee, Q.M. & Marietti, M. Global burden of NAFLD and NASH: trends, 631 predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(2018). 632 3. Carr, R.M., Oranu, A. & Khungar, V. Nonalcoholic Fatty Liver Disease: Pathophysiology and 633 Management. Gastroenterol Clin North Am 45, 639-652 (2016). 634 4. Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice 635 guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328-357 636 (2018). 637 5. Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. & Sanyal, A.J. Mechanisms of NAFLD 638 development and therapeutic strategies. Nat Med 24, 908-922 (2018). 639 6. Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A.J. Modeling the epidemic of 640 nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. 641 Hepatology 67, 123-133 (2018). 642 7. Sookoian, S. & Pirola, C.J. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol 643 Hepatol 23, 1-12 (2017). 644 Jarvis, H. et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty 8. 645 liver disease (NAFLD): A systematic review and meta-analysis of population-based observational 646 studies. PLoS Med 17, e1003100 (2020). Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver 647 9. 648 disease. Nat Genet 40, 1461-5 (2008). 649 Yuan, X. et al. Population-based genome-wide association studies reveal six loci influencing 10. 650 plasma levels of liver enzymes. Am J Hum Genet 83, 520-8 (2008). 651 Chambers, J.C. et al. Genome-wide association study identifies loci influencing concentrations of 11. 652 liver enzymes in plasma. Nat Genet 43, 1131-8 (2011). 653 12. Speliotes, E.K. et al. Genome-wide association analysis identifies variants associated with 654 nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7, 655 e1001324 (2011). 656 13. Feitosa, M.F. et al. The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and 657 hepatic inflammation in the NHLBI Family Heart Study. Atherosclerosis 228, 175-80 (2013). 658 Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers 14. 659 susceptibility to nonalcoholic fatty liver disease. Nat Genet 46, 352-6 (2014). 660 15. Liu, Y.L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-661 alcoholic fatty liver disease. Nat Commun 5, 4309 (2014). 662 16. Abul-Husn, N.S. et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver 663 Disease. N Engl J Med 378, 1096-1106 (2018). 664 17. Young, K.A. et al. Genome-Wide Association Study Identifies Loci for Liver Enzyme 665 Concentrations in Mexican Americans: The GUARDIAN Consortium. Obesity (Silver Spring) 27, 666 1331-1337 (2019). 667 18. Namjou, B. et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify 668 new trait-associated genes and pathways across eMERGE Network. BMC Med 17, 135 (2019). 669 19. Emdin, C.A. et al. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene 670 and protection against liver disease. PLoS Genet 16, e1008629 (2020). 671 Anstee, Q.M. et al. Genome-wide association study of non-alcoholic fatty liver and 20. 672 steatohepatitis in a histologically characterised cohort(). J Hepatol 73, 505-515 (2020).

673	21.	Serper, M. <i>et al.</i> Validating a Non-Invasive Non-Alcoholic Fatty Liver Phenotype in the Million
6/4		Veteran Program. PLoS One (in press)(2020).
675 676	22.	features of nonalcoholic Fatty liver disease. <i>Gastroenterology</i> 139 , 1567-76, 1576 e1-6 (2010).
677 678	23.	Locke, A.E. <i>et al.</i> Genetic studies of body mass index yield new insights for obesity biology. Nature 518 , 197, 206 (2015)
670	24	Nature 516 , 157-200 (2013). Venge L et al. Mote analysis of geneme wide association studies for height and hedy mass
680	24.	index in approximately 700000 individuals of European ancestry. <i>Hum Mol Genet</i> 27 , 3641-3649
681		(2018).
682	25.	Vujković, M. <i>et al.</i> Discovery of 318 new risk loci for type 2 diabetes and related vascular
683 684		outcomes among 1.4 million participants in a multi-ancestry meta-analysis. <i>Nat Genet</i> 52 , 680- 691 (2020).
685	26.	Evangelou, E. <i>et al.</i> Genetic analysis of over 1 million people identifies 535 new loci associated
686		with blood pressure traits. <i>Nat Genet</i> 50 , 1412-1425 (2018).
687 688	27.	Klarin, D. <i>et al.</i> Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program, <i>Nat Genet</i> 50 , 1514-1523 (2018)
689	28	Consortium G.T. The Genotype-Tissue Expression (GTEx) project Nat Genet 45, 580-5 (2013)
690	29.	Gaziano, J.M. <i>et al.</i> Million Veteran Program: A mega-biobank to study genetic influences on
602	20	nealth and disease. J Clin Epidemiol 70 , 214-23 (2016).
692 602	30.	Hayward, K.L. <i>et al.</i> Detecting non-alconolic fatty liver disease and fisk factors in health
604	21	databases: accuracy and limitations of the ICD-10-AWI. Bivis Open Gastroenterol 8(2021).
094 605	31.	Husain, N. <i>et al.</i> Nonaiconolic fatty liver disease (NAFLD) in the veterans Administration
695		Aliment Degree and Validation of an algorithm for NAFLD using automated data.
607	22	Anneni Pharmacol Ther 40 , 949-94 (2014).
698	32.	association studies. <i>Am J Hum Gen</i> 105 , 763-772 (2019).
699	33.	de Vries, P.S. et al. Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating
700		Gene-Alcohol Interactions. Am J Epidemiol 188 , 1033-1054 (2019).
701	34.	Chen, V.L. et al. Genome-wide association study of serum liver enzymes implicates diverse
702		metabolic and liver pathology. <i>Nat Commun</i> 12 , 816 (2021).
703	35.	Pazoki, R. et al. enetic analysis in European ancestry individuals identifies 517 loci associated
704		with liver enzymes. <i>Nat Commun (in press)(</i> 2021).
705	36.	Stender, S. et al. Relationship between genetic variation at PPP1R3B and levels of liver glycogen
706		and triglyceride. <i>Hepatology</i> 67 , 2182-2195 (2018).
707	37.	Finucane, H.K. et al. Partitioning heritability by functional annotation using genome-wide
708		association summary statistics. <i>Nat Genet</i> 47 , 1228-35 (2015).
709	38.	Bulik-Sullivan, B.K. et al. LD Score regression distinguishes confounding from polygenicity in
710		genome-wide association studies. <i>Nat Genet</i> 47 , 291-5 (2015).
711	39.	Finucane, H.K. et al. Heritability enrichment of specifically expressed genes identifies disease-
712		relevant tissues and cell types. Nat Genet 50 , 621-629 (2018).
713	40.	Stephens, C.R. et al. The Impact of Education and Age on Metabolic Disorders. Front Public
714		Health 8 , 180 (2020).
715	41.	Wakefield, J. Bayes factors for genome-wide association studies: comparison with P-values.
716		Genet Epidemiol 33 , 79-86 (2009).
717	42.	Adzhubei, I., Jordan, D.M. & Sunyaev, S.R. Predicting functional effect of human missense
718		mutations using PolyPhen-2. Curr Protoc Hum Genet Chapter 7, Unit7 20 (2013).
719	43.	Ng, M.C. et al. Meta-analysis of genome-wide association studies in African Americans provides
720		insights into the genetic architecture of type 2 diabetes. <i>PLoS Genet</i> 10 , e1004517 (2014).

721 722	44.	Caliskan, M. <i>et al.</i> Genetic and Epigenetic Fine Mapping of Complex Trait Associated Loci in the Human Liver. <i>Am J Hum Genet</i> 105 . 89-107 (2019).
723	45.	Baxter, M. et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells
724		better mimic fetal rather than adult hepatocytes. <i>J Hepatol</i> 62 , 581-9 (2015).
725 726	46.	Brancale, J. & Vilarinho, S. A single cell gene expression atlas of 28 human livers. <i>J Hepatol</i> (2021).
727	47.	Goldstein, J.A. <i>et al.</i> LabWAS: novel findings and study design recommendations from a meta-
728		analysis of clinical labs in two independent biobanks. <i>medRxiv</i> , 2020.04.08.19011478 (2020).
729	48.	Sticova, E. & Jirsa, M. ABCB4 disease: Many faces of one gene deficiency. Ann Hepatol 19, 126-
730		133 (2020).
731	49.	Gudbjartsson, D.F. <i>et al.</i> Large-scale whole-genome sequencing of the Icelandic population. <i>Nat</i>
732		Genet 47 , 435-44 (2015).
733	50.	Stattermaver, A.F., Halilbasic, E., Wrba, F., Ferenci, P. & Trauner, M. Variants in ABCB4 (MDR3)
734		across the spectrum of cholestatic liver diseases in adults. <i>J Hepatol</i> 73 , 651-663 (2020).
735	51.	Dwyer, A. et al. Influence of glycogen on liver density: computed tomography from a metabolic
736		perspective. J Comput Assist Tomoar 7, 70-3 (1983).
737	52.	Mehta, M.B. <i>et al.</i> Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes
738		hepatic glycogen synthesis and thereby regulates fasting energy homeostasis. J Biol Chem 292.
739		10444-10454 (2017).
740	53.	Wang, L. <i>et al.</i> NADP modulates RNA m(6)A methylation and adipogenesis via enhancing FTO
741		activity. Nat Chem Biol 16 . 1394-1402 (2020).
742	54.	Wang, C.Y. <i>et al.</i> Loss of FTO in adipose tissue decreases Angptl4 translation and alters
743		triglyceride metabolism. Sci Signal 8. ra127 (2015).
744	55.	Chen. Z. <i>et al.</i> Functional Screening of Candidate Causal Genes for Insulin Resistance in Human
745		Preadipocytes and Adipocytes. Circ Res 126 , 330-346 (2020).
746	56.	Nielsen, J.B. <i>et al.</i> Loss-of-function genomic variants highlight potential therapeutic targets for
747		cardiovascular disease. <i>Nat Commun</i> 11 , 6417 (2020).
748	57.	Fagerberg, L. <i>et al.</i> Analysis of the human tissue-specific expression by genome-wide integration
749		of transcriptomics and antibody-based proteomics. <i>Mol Cell Proteomics</i> 13 , 397-406 (2014).
750	58.	Duff, M.O. <i>et al.</i> Genome-wide identification of zero nucleotide recursive splicing in Drosophila.
751		Nature 521 , 376-9 (2015).
752	59.	Jamialahmadi, O. <i>et al.</i> Exome-Wide Association Study on Alanine Aminotransferase Identifies
753		Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease.
754		Gastroenterology 160 , 1634-1646 e7 (2021).
755	60.	Hammond, L.E. <i>et al.</i> Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have
756		reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition.
757		Mol Cell Biol 22 , 8204-14 (2002).
758	61.	Cuchel, M. <i>et al.</i> Inhibition of microsomal triglyceride transfer protein in familial
759		hypercholesterolemia. N Engl J Med 356 , 148-56 (2007).
760	62.	Soubeyrand, S., Martinuk, A. & McPherson, R. TRIB1 is a positive regulator of hepatocyte nuclear
761		factor 4-alpha. <i>Sci Rep</i> 7 , 5574 (2017).
762	63.	Laudadio, I. et al. A feedback loop between the liver-enriched transcription factor network and
763		miR-122 controls hepatocyte differentiation. <i>Gastroenterology</i> 142 , 119-29 (2012).
764	64.	Kim, K. <i>et al.</i> RORalpha controls hepatic lipid homeostasis via negative regulation of
765		PPARgamma transcriptional network. Nat Commun 8, 162 (2017).
766	65.	Kim, J.Y., Han, Y.H., Nam, M.W., Kim, H.J. & Lee, M.O. RORalpha suppresses interleukin-6-
767		mediated hepatic acute phase response. <i>Sci Rep</i> 9 , 11798 (2019).

768	66.	Laatsch, A. et al. Low density lipoprotein receptor-related protein 1 dependent endosomal
769		trapping and recycling of apolipoprotein E. <i>PLoS One</i> 7 , e29385 (2012).
770	67.	Moon, J.H. <i>et al.</i> Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of
771		the beneficial effect of thiazolidinediones on atherogenic dyslipidemia. J Mol Endocrinol 49, 165-
772		74 (2012).
773	68.	Skat-Rordam, J., Hoiland Ipsen, D., Lykkesfeldt, J. & Tyeden-Nyborg, P. A role of peroxisome
774		proliferator-activated receptor gamma in non-alcoholic fatty liver disease. <i>Basic Clin Pharmacol</i>
775		Toxicol 124 , 528-537 (2019).
776	69.	Sanval, A.J. <i>et al.</i> Pioglitazone, vitamin E. or placebo for nonalcoholic steatohepatitis. <i>N Engl J</i>
777		Med 362 , 1675-85 (2010).
778	70.	Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Thiazolidinediones and Advanced Liver
779		Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med 177 , 633-640 (2017).
780	71.	Ratziu. V. <i>et al.</i> Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the
781		randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT)
782		Trial. Gastroenterology 135 , 100-10 (2008).
783	72.	Ratziu, V. et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the
784		fatty liver improvement by rosiglitazone therapy (ELIRT 2) extension trial <i>Hepgtology</i> 51 445-53
785		(2010).
786	73.	Cusi, K. <i>et al.</i> Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis
787		and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial Ann Intern Med 165 305-15
788		(2016)
789	74.	Luc, G. <i>et al.</i> Distribution of apolipoprotein F between apo B- and non apo B-containing
790		lipoproteins according to apo E phenotype. Atherosclerosis 131 , 257-62 (1997)
791	75	Nakaya Y. Schaefer F. L. & Brewer H.B. Ir Activation of human post heparin lipoprotein lipase
792	, 0,	by apolipoprotein H (beta 2-glycoprotein I) <i>Biochem Biophys Res Commun</i> 95 1168-72 (1980)
793	76	Lin KY et al. Evidence for inhibition of low density lipoprotein oxidation and cholesterol
794	, 0,	accumulation by apolipoprotein H (beta2-glycoprotein I) Life Sci 69 707-19 (2001)
795	77	Mabile L et al. Secreted apolipoprotein E reduces macrophage-mediated LDL oxidation in an
796		isoform-dependent way <i>I Cell Biochem</i> 90 766-76 (2003)
797	78	Karavia E.A. Papachristou D.I. Kotsikogianni I. Giopanou I.& Kypreos K.E. Deficiency in
798	, 0,	apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice
799		<i>FFBS</i> / 278 3119-29 (2011)
800	79	Schierwagen B <i>et al.</i> Seven weeks of Western diet in anolinoprotein-E-deficient mice induce
801	, , ,	metabolic syndrome and non-alcoholic steatohenatitis with liver fibrosis. Sci Ren 5, 12931
802		(2015)
803	80.	Tilg. H., Adolph. T.F. & Moschen, A.R. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty
804		Liver Disease: Revisited After a Decade <i>Hengtology</i> 73 833-842 (2021)
805	81	Hamada M Tsunakawa Y leon H Yaday MK & Takabashi S Role of MafB in macrophages
806	01.	Exp Anim 69 1-10 (2020)
807	82	Tran M T <i>et al</i> MafB deficiency accelerates the development of obesity in mice <i>FEBS Open Bio</i>
808	02.	6 540-7 (2016)
809	83	Hamada M <i>et al</i> MafB promotes atherosclerosis by inhibiting foam-cell apoptosis <i>Nat</i>
810	00.	Commun 5 3147 (2014)
811	84	Stoffel W et al. Obesity resistance and deregulation of linogenesis in Delta6-fatty acid
812	57.	desaturase (EADS2) deficiency EMBO Rep 15 (110-20 (2014)
813	85	Ecker 1 <i>et al</i> Induction of fatty acid synthesis is a key requirement for phagocytic
81/	00.	differentiation of human monocytes. Proc Natl Acad Sci U.S. A 107 7817 22 (2010)
014		$\mathbf{A} = \mathbf{A} = $

816 Pathways Underlying NAFLD: Towards New Treatment Strategies. Trends Mol Med	24 458-471
817 (2018)	21, 100 171
818 87 Hotamisligil G.S. Inflammation and metabolic disorders. <i>Nature</i> 444 , 860-7 (2006)	
810 88 Negrin K A <i>et al.</i> II -1 signaling in obesity-induced henatic linegenesis and steatosic	E PLOS One Q
820 e107265 (2014)	s. FLOS OTTE 3 ,
821 89 Osborn O & Olefsky I M The cellular and signaling networks linking the immune	system and
822 metabolism in disease <i>Nat Med</i> 18 363-74 (2012)	system and
823 90 Tan O <i>et al.</i> The Role of II -1 Family Members and Kunffer Cells in Liver Regenerati	on <i>Biomed</i>
824 <i>Res Int</i> 2016 . 6495793 (2016).	on biomed
825 91. Gieling, R.G., Wallace, K. & Han, Y.P. Interleukin-1 participates in the progression fr	om liver
826 injury to fibrosis. <i>Am J Physiol Gastrointest Liver Physiol</i> 296 . G1324-31 (2009).	
827 92 Meier R P H <i>et al</i> Interleukin-1 Recentor Antagonist Modulates Liver Inflammatio	n and Fibrosis
828 in Mice in a Model-Dependent Manner Int I Mol Sci 20 (2019)	
829 93 Gebrke N <i>et al</i> Henatocyte-specific deletion of II 1-RI attenuates liver injury by blo	ocking II -1
830 driven autoinflammation. <i>J Hepatol</i> 68 , 986-995 (2018).	
831 94. Larsen, C.M. <i>et al.</i> Interleukin-1-receptor antagonist in type 2 diabetes mellitus. <i>N I</i>	Fnal I Med
832 356 , 1517-26 (2007).	
833 95. van Asseldonk, E.J. <i>et al.</i> One week treatment with the IL-1 receptor antagonist and	akinra leads
to a sustained improvement in insulin sensitivity in insulin resistant patients with ty	/pe 1
835 diabetes mellitus. <i>Clin Immunol</i> 160 . 155-62 (2015).	,
836 96. Baneriee, A. & Singh, J. Remodeling adipose tissue inflammasome for type 2 diabet	es mellitus
837 treatment: Current perspective and translational strategies. <i>Bioena Transl Med</i> 5. et	e10150
838 (2020).	
839 97. Han, Y.H. <i>et al.</i> A maresin 1/RORalpha/12-lipoxygenase autoregulatory circuit prev	ents
840 inflammation and progression of nonalcoholic steatohepatitis. <i>J Clin Invest</i> 129 , 169	84-1698
841 (2019).	
842 98. Chai, C. <i>et al.</i> Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in N	/lice via Up-
regulation of MicroRNA 122, <i>Gastroenterology</i> 159 , 999-1014 e9 (2020).	
844 99. West, L.C. & Cresswell, P. Expanding roles for GILT in immunity. <i>Curr Opin Immunol</i>	/ 25 . 103-8
845 (2013).	,
846 100. Chiang, H.S. & Maric, M. Lysosomal thiol reductase negatively regulates autophagy	by altering
847 glutathione synthesis and oxidation. <i>Free Radic Biol Med</i> 51 , 688-99 (2011).	, 0
848 101. Chapoval, A.I. et al. B7-H3: a costimulatory molecule for T cell activation and IFN-ga	amma
849 production. <i>Nat Immunol</i> 2 , 269-74 (2001).	
850 102. Sun, T.W. et al. B7-H3 is expressed in human hepatocellular carcinoma and is assoc	iated with
851 tumor aggressiveness and postoperative recurrence. <i>Cancer Immunol Immunother</i>	61 , 2171-82
852 (2012)	
853 103. Kang, F.B. <i>et al.</i> B7-H3 promotes aggression and invasion of hepatocellular carcinor	ma bv
854 targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathy	, wav. Cancer
855 Cell Int 15 , 45 (2015).	7
856 104. Li. L. et al. Identification of key genes in nonalcoholic fatty liver disease progression	n based on
857 bioinformatics analysis. <i>Mol Med Rep</i> 17 , 7708-7720 (2018).	
858 105. Baeza-Raja, B. <i>et al.</i> Pharmacological inhibition of P2RX7 ameliorates liver injury by	reducing
859 inflammation and fibrosis. <i>PLoS One</i> 15 . e0234038 (2020).	0
860 106. Di Virgilio, F., Dal Ben, D., Sarti, A.C., Giuliani, A.L. & Falzoni, S. The P2X7 Receptor i	n Infection
861 and Inflammation. <i>Immunity</i> 47 , 15-31 (2017).	

862	107.	Giuliani, A.L., Sarti, A.C., Falzoni, S. & Di Virgilio, F. The P2X7 Receptor-Interleukin-1 Liaison.
863		Front Pharmacol 8 , 123 (2017).
864	108.	Willebrords, J. et al. Protective effect of genetic deletion of pannexin1 in experimental mouse
865		models of acute and chronic liver disease. Biochim Biophys Acta Mol Basis Dis 1864, 819-830
866		(2018).
867	109.	Cooreman, A. et al. Connexin and Pannexin (Hemi)Channels: Emerging Targets in the Treatment
868		of Liver Disease. <i>Hepatology</i> 69 , 1317-1323 (2019).
869	110.	Cai, B. et al. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell
870		Metab 31 , 406-421 e7 (2020).
871	111.	Patin, E. <i>et al.</i> Genome-wide association study identifies variants associated with progression of
872		liver fibrosis from HCV infection. <i>Gastroenterology</i> 143 . 1244-1252 e12 (2012).
873	112.	Wen, Y. & Ju. C. MerTK - A Novel Potential Target to Treat NASH Fibrosis. <i>Hepgtology</i> (2020).
874	113	Hunter-Zinck H <i>et al.</i> Genotyping Array Design and Data Quality Control in the Million Veteran
875	1101	Program Am I Hum Genet 106 535-548 (2020)
876	114	Kranzler, H.R. et al. Genome-wide association study of alcohol consumption and use disorder in
877	±± 1.	274 424 individuals from multiple populations. <i>Nat Commun</i> 10 1499 (2019)
878	115	Lustice $\Lambda \subset et al \Lambda \square D \square C$ and $I \square C codes as phenotypes for harmful alcohol use; association$
879	115.	with ADH1B polymorphisms in two US populations. Addiction 113 , 2214-2224 (2018)
880	116	Chang C C et al. Second generation PLINK: rising to the challenge of larger and richer datasets
881	110.	Chang, C.C. <i>et al.</i> Second-generation relink. Insing to the chanenge of larger and ficher datasets.
887	117	Willer C. L. Li V. & Abesacis C. P. METAL: fact and efficient meta analysis of genomewide
002	117.	while, C.J., Li, Y. & Abecasis, G.K. METAL. Tast and efficient meta-analysis of genomewide
003	110	association scans. <i>Bioinjormatics</i> 26 , 2190-1 (2010).
004	118.	Hutchinson, A., Watson, H. & Wallace, C. Correcting the coverage of credible sets in Bayesian
00J 00Z	110	genetic fine-mapping. <i>Diorxiv, 1</i> 81062 (2019).
000	119.	nads, M.E. et al. Machine learning enables new insights into clinical significance of and genetic
00/	120	contributions to liver fat accumulation. <i>medrxiv</i> , 2020.09.03.2018/195 (2020).
000	120.	macLean, M.T. <i>et al.</i> Linking abdominal imaging traits to electronic health record phenotypes.
889	101	mearxiv, 2020.09.08.20190330 (2020). Mattack sell but st. Consume Mide Associations Delated to Usuatio Uistala surin Neurolaskalis
890	121.	Wattacheril, J. <i>et al.</i> Genome-Wide Associations Related to Hepatic Histology in Nonaiconolic
891	400	Fatty Liver Disease in Hispanic Boys. J Pediatr 190 , 100-107 e2 (2017).
892	122.	Patton, H.M. et al. Clinical correlates of histopathology in pediatric honalcoholic steatonepatitis.
893	400	Gastroenterology 135 , 1961-1971 e2 (2008).
894	123.	Kleiner, D.E. <i>et al.</i> Design and validation of a histological scoring system for nonalconolic fatty
895	124	liver disease. <i>Hepatology</i> 41 , 1313-21 (2005).
890	124.	Lin, H.J. <i>et al.</i> Home use of a compact, 12lead ECG recording system for newborns. J
897	405	Electrocardiol 53 , 89-94 (2019).
898	125.	Weinshilboum, R.M. & Wang, L. Pharmacogenomics: Precision Medicine and Drug Response.
899		Mayo Clin Proc 92 , 1711-1722 (2017).
900	126.	Gawrieh, S. <i>et al.</i> A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response
901		to Obeticholic Acid in Patients With NASH. <i>Hepatol Commun</i> 3 , 1571-1584 (2019).
902	127.	Simon, J.A. <i>et al.</i> Phenotypic predictors of response to simvastatin therapy among African-
903		Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol 97,
904		843-50 (2006).
905	128.	Hardy, T. <i>et al.</i> The European NAFLD Registry: A real-world longitudinal cohort study of
906		nonalcoholic fatty liver disease. <i>Contemp Clin Trials</i> 98 , 106175 (2020).
907	129.	Dewey, F.E. et al. Distribution and clinical impact of functional variants in 50,726 whole-exome
908		sequences from the DiscovEHR study. <i>Science</i> 354 (2016).

909	130.	Harrison, S.A. <i>et al.</i> Selonsertib for patients with bridging fibrosis or compensated cirrhosis due
910		to NASH: Results from randomized phase III STELLAR trials. <i>J Hepatol</i> 73 , 26-39 (2020).
911	131.	Roden, D.M. et al. Development of a large-scale de-identified DNA biobank to enable
912		personalized medicine. <i>Clin Pharmacol Ther</i> 84 , 362-9 (2008).
913	132.	Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat
914		Genet 47 , 1236-41 (2015).
915	133.	Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. <i>Nature</i>
916		489 , 57-74 (2012).
917	134.	Roadmap Epigenomics, C. <i>et al.</i> Integrative analysis of 111 reference human epigenomes.
918		Nature 518 , 317-30 (2015).
919	135.	Andersson, R. <i>et al.</i> An atlas of active enhancers across human cell types and tissues. <i>Nature</i>
920		507 , 455-461 (2014).
921	136.	Fehrmann, R.S. <i>et al.</i> Gene expression analysis identifies global gene dosage sensitivity in cancer.
922		Nat Genet 47 , 115-25 (2015).
923	137.	Cahoy, J.D. et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new
924		resource for understanding brain development and function. J Neurosci 28, 264-78 (2008).
925	138.	Heng, T.S., Painter, M.W. & Immunological Genome Project, C. The Immunological Genome
926		Project: networks of gene expression in immune cells. <i>Nat Immunol</i> 9, 1091-4 (2008).
927	139.	Pers, T.H. et al. Biological interpretation of genome-wide association studies using predicted
928		gene functions. Nat Commun 6 , 5890 (2015).
929	140.	Schmidt, E.M. et al. GREGOR: evaluating global enrichment of trait-associated variants in
930		epigenomic features using a systematic, data-driven approach. Bioinformatics 31 , 2601-6 (2015).
931	141.	McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122 (2016).
932	142.	Genomes Project, C. <i>et al.</i> A global reference for human genetic variation. <i>Nature</i> 526 , 68-74
933		(2015).
934	143.	Chesi, A. et al. Genome-scale Capture C promoter interactions implicate effector genes at GWAS
935		loci for bone mineral density. <i>Nat Commun 10,</i> 1260 (2019).
936	144.	Pashos, E.E. et al. Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells
937		Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. Cell Stem Cell 20, 558-570
938		e10 (2017).
939	145.	Wingett, S. <i>et al.</i> HiCUP: pipeline for mapping and processing Hi-C data. <i>F1000Res</i> 4 , 1310
940		
941	146.	Cairns, J. <i>et al.</i> CHICAGO: robust detection of DNA looping interactions in Capture HI-C data.
942	1 4 7	Genome Biol 17, 127 (2016).
945	147.	Szkiarczyk, D. et al. Si king VII: protein-protein association networks with increased coverage,
944		supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47,
94J 046	110	Carliano Taliun SA, at al Evoluting and visualizing large scale genetic associations by using
040	140.	DepWob Nat Canat 52 550 552 (2020)
948	1/19	Denny 10° et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover
949	145.	gene-disease associations. <i>Bioinformatics</i> 26 , 1205-10 (2010)
950	150	Lob P. R. et al. Reference-based phasing using the Hanlotyne Reference Consortium papel. Nat
951	150.	Genet 48 1443-1448 (2016)
952	151	Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-
953	101.	scale genetic association studies. <i>Nat Genet</i> 50 , 1335-1341 (2018)
954	152.	Elsworth, B. <i>et al.</i> The MRC IEU OpenGWAS data infrastructure. <i>bioRxiv</i> . 2020.08.10.244293
955		(2020).

42

956 957	153.	Shin, S.Y. <i>et al</i> . An atlas of genetic influences on human blood metabolites. <i>Nat Genet</i> 46 , 543- 550 (2014).
958 959	154.	Kettunen, J. <i>et al.</i> Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. <i>Nat Commun</i> 7 , 11122 (2016).
960 961	155.	Hemani, G. <i>et al.</i> The MR-Base platform supports systematic causal inference across the human phenome. <i>Elife</i> 7 (2018).
962	156.	Sun, B.B. <i>et al.</i> Genomic atlas of the human plasma proteome. <i>Nature</i> 558 , 73-79 (2018).
963 964	157.	Giambartolomei, C. <i>et al.</i> Bayesian test for colocalisation between pairs of genetic association
965	158	Giri Λ et al. Trans-ethnic association study of blood pressure determinants in over 750.000
966	150.	individuals. Nat Genet 51 , 51-62 (2019).
967 968	159.	Pulit, S.L. <i>et al.</i> Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. <i>Hum Mol Genet</i> 28 , 166-174 (2019).
969	160.	Teumer, A. et al. Genome-wide association meta-analyses and fine-mapping elucidate pathways
970		influencing albuminuria. <i>Nat Commun</i> 10 , 4130 (2019).
971 972	161.	Tin, A. <i>et al.</i> Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. <i>Nat Genet</i> 51 , 1459-1474 (2019).
973	162.	Wuttke, M. et al. A catalog of genetic loci associated with kidney function from analyses of a
974		million individuals. <i>Nat Genet</i> 51 , 957-972 (2019).
975 976	163.	Astle, W.J. <i>et al.</i> The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. <i>Cell</i> 167 , 1415-1429 e19 (2016).
977	164.	Guo, H. <i>et al.</i> Integration of disease association and eQTL data using a Bayesian colocalisation
978		approach highlights six candidate causal genes in immune-mediated diseases. <i>Hum Mol Genet</i>
979		24 , 3305-13 (2015).
980	165.	Lambert, S.A. et al. The Human Transcription Factors. Cell 175 , 598-599 (2018).
981	166.	Garcia-Alonso, L., Holland, C.H., Ibrahim, M.M., Turei, D. & Saez-Rodriguez, J. Benchmark and
982		integration of resources for the estimation of human transcription factor activities. Genome Res
983		29 , 1363-1375 (2019).
984	167.	Turei, D., Korcsmaros, T. & Saez-Rodriguez, J. OmniPath: guidelines and gateway for literature-
985		curated signaling pathway resources. Nat Methods 13 , 966-967 (2016).
986	168.	Ceccarelli, F., Turei, D., Gabor, A. & Saez-Rodriguez, J. Bringing data from curated pathway
987		resources to Cytoscape with OmniPath. <i>Bioinformatics</i> 36 , 2632-2633 (2020).
988		

43

990 Methods

We performed a large-scale trans-ancestry NAFLD GWAS in the Million Veteran Program. We subsequently conducted analyses to facilitate the prioritization of these individual findings, including transcriptome-wide predicted gene expression, secondary signal analysis, coding variant mapping, variant-to-gene mapping, and pleiotropy analysis to fine-map the genomic loci to putatively causal genes and biological mechanisms.

996

997 Discovery cohort in Million Veteran Program.

998 The Million Veteran Program (MVP) is a mega-biobank that was launched in 2011 and 999 supported entirely by the Veterans Health Administration (VA) Office of Research and 1000 Development in the United States (US) of America, to develop a genetic repository of US 1001 Veterans with additional information through the VA electronic health record system and MVP 1002 questionnaires to learn how genes, lifestyle and military exposure affect health and disease. 1003 The MVP received ethical and study protocol approval from the VA Central Institutional Review 1004 Board (IRB) in accordance with the principles outlined in the Declaration of Helsinki. Over 60 VA 1005 Medical Centers have participated in this study nationally. The specific design, initial demographics of the MVP have been detailed previously²⁹. Electronic health record information 1006 1007 from the VA's Corporate Data Warehouse (CDW) was used for clinical and demographic 1008 information. For genetic analyses, DNA extracted from whole blood was genotyped in 1009 customized Affymetrix Axiom Array which contains a total of 723,305 SNPs enriched for: 1) low 1010 frequency variants in AA and HISP populations, and 2) variants associated with diseases

44

1011 common to the VA population²⁹. Further quality control procedures have been previously
 1012 described¹¹³.

Proxy NAFLD Phenotype: MVP NAFLD phenotype definitions were developed by combining a 1013 1014 previously published VA CDW ALT-based approach with non-invasive clinical parameters available to practicing clinicians at the point of care ^{21,31}. The primary NAFLD phenotype 1015 1016 (labeled "ALT-threshold") was defined by: (i) elevated ALT >40 U/L for men or >30 U/L for 1017 women during at least two time points at least 6 months apart within a two-year window 1018 period at any point prior to enrollment and (ii) exclusion of other causes of liver disease (e.g., 1019 presence of chronic viral hepatitis B or C (defined as positive hepatitis C RNA > 0 international 1020 units/mL or positive hepatitis B surface antigen), chronic liver diseases or systemic conditions 1021 (e.g., hemochromatosis, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune 1022 hepatitis, alpha-1-antitrypsin deficiency, sarcoidosis, metastatic liver cancer, secondary biliary 1023 cirrhosis, Wilson's disease), and/or alcohol use disorder (e.g., alcohol use disorder, alcoholic 1024 liver disease, alcoholic hepatitis and/or ascites, alcoholic fibrosis and sclerosis of liver, alcoholic 1025 cirrhosis of liver and/or ascites, alcoholic hepatic failure and/or coma, and unspecified alcoholic 1026 liver disease). The control group was defined by having a: normal ALT (≤30 U/L for men, ≤20 U/L 1027 for women) and no apparent causes of liver disease or alcohol use disorder or related 1028 conditions²¹. Habitual alcohol consumption was assessed with the age-adjusted Alcohol Use 1029 Disorders Identification Test (AUDIT-C) score, a validated questionnaire annually administered by VA primary care practitioners and used previously in MVP^{114,115}. Demographics of the NAFLD 1030 1031 cohort are shown in **Supplementary Table 1**.

45

46

1034 Single-variant autosomal analyses.

We tested imputed SNPs that passed quality control (i.e. HWE > 1×10^{-10} , INFO > 0.3, call rate > 1035 1036 0.975) for association with NAFLD through logistic regression assuming an additive model of 1037 variants with MAF > 0.1% in European American (EA), and MAF > 1% in African Americans (AA), Hispanics (HISP), and Asians (ASN) using PLINK2a software¹¹⁶. Indels were excluded from 1038 1039 analysis. Covariates included age, gender, age-adjusted AUDIT-C score, and first 10 principal 1040 components (PC's) of genetic ancestry. We aggregated association summary statistics from the 1041 ancestry-specific analyses and performed a trans-ancestry meta-analysis. The association 1042 summary statistics for each analysis were meta-analyzed in a fixed-effects model using METAL with inverse-variance weighting of log odds ratios¹¹⁷. Variants were clumped using a range of 1043 500kb and/or CEU r^2 LD > 0.05, and were considered genome-wide significant if they passed the 1044 1045 conventional p-value threshold of 5×10^{-8} . Trans-ancestry and ancestry-specific summary statistics are displayed in Supplementary Tables 2-5. 1046

1047

1048 Secondary signal analysis.

1049 The PLINK --condition and --condition-list parameters were used to conduct stepwise 1050 conditional analyses on individual level data in MVP to detect ancestry-specific distinct 1051 association signals nearby lead SNPs. Regional SNPs were eligible if they were located within 1052 500kb of lead SNP, had a MAF >1% and passed standard quality control criteria (INFO > 0.3, 1053 HWE P > $1.0x10^{-10}$, call rate > 0.975). Logistic regression was performed in a stepwise fashion, 1054 starting with a regional association analysis with the following set of covariates: lead SNP 1055 imputed allele dosage, age, gender, and 10 PC's of genetic ancestry. If the corresponding

47

1056	output file contained SNP(s) that reached locus-wide significance (P < 1.0×10^{-5}), the most
1057	significant SNP was selected and added to the covariate set. The regression was repeated until
1058	no locus-wide significant SNPs remained. Secondary signals are shown in Supplementary Table
1059	11.
1060	
1061	Credible Sets.
1062	We calculated Wakefield's approximate Bayes' factors ⁴¹ based on the marginal summary
1063	statistics of the trans-ancestry meta-analysis and ancestry specific summary statistics using the
1064	CRAN R package corrcoverage ¹¹⁸ . For each locus, the posterior probabilities of each variant
1065	being causal were calculated and a 95% credible set was generated which contains the
1066	minimum set of variants that jointly have at least 95% posterior probability (PP) of including the
1067	causal variant (Supplementary Tables 12-15).
1068	

1069 External validation in a Liver Imaging cohort.

1070 A replication lookup of lead loci was performed to evaluate the extent to which genetic 1071 predictors of hepatocellular injury (cALT) correspond with guantitative hepatic fat derived from 1072 computed tomography (CT) / magnetic resonance imaging (MRI)-measured hepatic fat in the 1073 Penn Medicine Biobank (PMBB), UK Biobank, Multi-Ethnic Study of Atherosclerosis (MESA), Framingham Heart Study (FHS), and University of Maryland Older Order Amish study 1074 1075 (Supplementary Table 8). Attenuation was measured in Hounsfield units. The difference 1076 between the spleen and liver attenuation was measured for PMBB; a ratio between liver 1077 attenuation/spleen attenuation was used for MESA and Amish; and liver attenuation/phantom

48

attenuation ratio in FHS as previously described by Speliotes et al¹². Abdominal MRI data from 1078 1079 UK Biobank data were used to quantify liver fat using a two-stage machine learning approach with deep convolutional neural networks¹¹⁹. CT-measured hepatic fat was estimated using a 1080 1081 multi-stage series of neural networks for presence of scan contrast and liver segmentation 1082 using convolutional neural networks. The PMBB included CT data on 2,979 EA and 1,250 AA 1083 participants¹²⁰, the FHS included a total of 3,011 EA participants, the Amish study 754 EA 1084 participants, and MESA contributed 1,525 EA, 1,048 AA, 923 HISP, and 360 ASN participants for 1085 concordance analysis. The UK Biobank included MRI image data from 36,703 EA participants. All cohorts underwent individual-level linear regression analysis on hepatic fat, adjusted for the 1086 1087 covariates of age, gender, first 10 principal components of genetic ancestry, and alcohol intake 1088 if available. If the lead SNP was not available in any of the studies, a proxy SNP in high LD with 1089 the lead variant was used $(r^2 > 0.7)$ or if no such variant was identified, the SNP was set to 1090 missing for that respective study. The study-specific ancestry-stratified summary statistics were 1091 first standardized to generate standard scores or normal deviates (z-scores), and then meta-1092 analyzed using METAL in a fixed-effects model with inverse-variance weighting of regression 1093 coefficients¹¹⁷. In a first round of meta-analysis, ancestry-specific summary statistics were 1094 generated, which then served as input for a subsequent round of meta-analysis that represents 1095 the trans-ancestry effects of our lead SNPs on quantitative hepatic fat.

1096

1097 External validation in a Liver Biopsy cohort

1098 Available data from the following groups contributed to the Liver Biopsy Cohort.

49

1099 Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN) studies with Hispanic 1100 Boys, FLINT, PIVENS and NASH Women Studies: Results from several studies of EA and HISP participants were included from the Lundquist Institute. The Hispanic cases are derived from 1101 1102 the NAFLD Pediatric Database | (NAFLD Peds DB1), a prospective, longitudinal, multicenter, 1103 observational study cohort of adults and children initiated in 2002 and contains over 4,400 1104 subjects¹²¹. Clinical and histologic features of database participants have been described by Patton et al¹²². Biopsy specimens were reviewed and scored centrally by the Non-Alcoholic 1105 1106 Steatohepatitis Clinical Research Network (NASH CRN) Pathology Committee according to the histology scoring system established by the NASH CRN¹²³. Genotyping was performed using the 1107 1108 Illumina HumanCNV370-Quadv3 BeadChip at the Medical Genetics Institute at Cedars-Sinai 1109 Medical Center (HumanCNV370-Quadv3 BeadChips; Illumina, San Diego, CA, USA). The Hispanic 1110 controls from NASH CRN are derived from the Long QT Screening (LQTS) study¹²⁴. Saliva 1111 samples were used for genotyping with the Illumina HumanCore-24 BeadChips at the Institute 1112 for Translational Genomics and Population Sciences of the Lundquist Institute at Harbor-UCLA 1113 Medical Center. For all Hispanic samples, SNP data were imputed to the 1000 Genomes Project 1114 phase 3 dataset version 5 (AMR population) on the Michigan imputation server. The final 1115 dataset consisted of 787 samples, including 208 cases from NASH Boys and 579 controls from 1116 LQTS, and the top 3 PCs were included in the association analysis.

1117 The European American NAFLD samples from Lundquist Institute are derived from 1118 FLINT, PIVENS, and NASH women studies, and the controls are derived from the Cholesterol 1119 and Atherosclerosis Pharmacogenetics (CAP) trial. The details of the <u>FLINT study</u> have been 1120 published previously¹²⁵. Liver histology was blindly and centrally assessed by the NASH Clinical

50

Research Network (NASH CRN) Pathology Committee according the NASH CRN system¹²³. A 1121 total of 244 patients with available DNA were genotyped of whom 198 (81%) were White¹²⁶. 1122 1123 Genotyping was performed using the Omni2.5 content GWAS chip. The PIVENS study, a study of Pioglitazone versus Vitamin E versus Placebo in non-diabetic adults has been described 1124 previously⁶⁹. Genotyping was performed on 432 PIVENS samples along with the FLINT samples 1125 1126 using the Omni2.5 content GWAS chip. Subjects were removed for failed genotyping, 1127 unresolvable gender discrepancies, being outliers by principal component analyses, and by relatedness. In total, 197 White samples remained in the analysis dataset. The NASH Women 1128 1129 study included a subset of patients who were into the NAFLD Database Study of NASH CRN 1130 whose liver biopsy specimens were reviewed and scored centrally by the NASH CRN Pathology Subcommittee. For the GWAS ancillary study²² genotyping was performed at the Medical 1131 1132 Genetics Institute at Cedars-Sinai Medical Center with the use of Infinium HD technology (HumanCNV370-Quadv3 BeadChips; Illumina, San Diego, CA). The controls for the European 1133 1134 American analysis from Lundquist Institute are derived from the CAP trial involved 944 healthy volunteers, 609 of whom were Caucasian¹²⁷. In total, 591 subjects were genotyped on the 1135 1136 Illumina HumanHap300 BeadChip or Illumina HumanCNV610-Quad beadchip. Imputation was 1137 performed using the Michigan Imputation Server with the reference panel of the Haplotype 1138 Reference Consortium (HRC) 1.1 release in 2016. After final QC of European American cohorts, 1139 the final 1,225 samples in the analysis including 650 cases and 575 controls, and the top 3 PCs 1140 for genetic ancestry were included in the association analysis. The NASH CRN database and 1141 clinical trials were reviewed and approved by the individual institutional review boards at each 1142 participating site. All participants signed an informed consent prior to their enrollment into

51

these consents and their de-identitied genetic data to be used for future liver disease research by the NASH CRN investigators and by their collaborators. These studies have been monitored by an NIDDK-sponsored data safety and monitoring board.

1146

1147 EPoS Consortium Cohort: Results from EPoS consortium cohort were included from Newcastle 1148 University. A total 1,483 histologically characterized NAFLD cases were included and 17,781 1149 genetically matched controls, with the cases recruited into the European NAFLD Registry 1150 (ClinicalTrials.gov Identifier: NCT04442334) from clinics at several leading European tertiary liver centres²⁰. Details of inclusion/exclusion criteria have previously been described^{20,128}. All 1151 1152 patients had undergone liver biopsy as part of the routine diagnostic workup for presumed 1153 NAFLD, and routinely assessed according to accepted criteria by experienced liver pathologists and scored using the well validated NIDDK NASH CRN system¹²³. Genotyping was performed 1154 1155 using the Illumina OmniExpress BeadChip by Edinburgh Clinical Research Centre. The 17,781 1156 population controls were recruited from existing genome-wide genotype data: Wellcome Trust 1157 Case Control Consortium, (n=5,159) typed on the Illumina Human1.2M-Duo; the Hypergenes 1158 cohort (n=1,520) typed on the Illumina Human1M-Duo, KORA (n=1,835) genotyped on the 1159 Illumina HumanOmni2.5 Exome chip, and Understanding Societies (n=9,267) typed on the 1160 Illumina HumanCoreExome chip. Overlapping SNPs that were well genotyped in all case and 1161 control cohorts were imputed together to the Haplotype Resource Consortium panel (HRC 1.1r 1162 2016) by the Michigan Imputation Server.

1163 <u>The Geisinger Health System (GHS) bariatric surgery cohort</u>: This consisted of 3,599 individuals
 1164 of European descent. Wedge biopsies of the liver were obtained intraoperatively during

52

1165 bariatric surgery, and liver histology was conducted by an experienced pathologist and 1166 subsequently re-reviewed by a second experienced pathologist using the NASH CRN scoring system¹²³. A total of 806 participants did not have NAFLD and were classified as controls, 1167 1168 whereas 2,793 were histologically characterized as having NAFLD. DNA sample preparation and whole-exome sequencing were performed at the Regeneron Genetics Centre¹²⁹. Exome capture 1169 1170 was performed using NimbleGen probes according to the manufacturer's recommended 1171 protocol (Roche NimbleGen) multiplexed samples were sequenced on an Illumina v4 HiSeg 2500. Raw sequence data from each run were uploaded to the DNAnexus platform for 1172 1173 sequence read alignment and variant identification.

1174 STELLAR-3 and ATLAS studies: Results from two trials from Gilead Sciences were included 1175 including phase 3 STELLAR-3 study (ClinicalTrials.gov Identifier: NCT03053050), and phase 2 1176 ATLAS study (ClinicalTrials.gov Identifier: NCT03449446) which were discontinued/terminated¹³⁰. Genotyping was performed using whole genome sequencing 1177 1178 (Illumina) aimed at 100x coverage. The PyVCF script was used to extract allele frequencies from 1179 VCF files generated using GATK4 pipeline with hg38 as reference genome.

<u>BioVU Biorepository:</u> BioVU subjects at Vanderbilt University underwent SNP genotyping using the Illumina Infinium Multi-Ethnic Genotyping Array (MEGAEX) platform and underwent QC analyses and imputation as previously described ¹³¹. Genetic data for were imputed using the Michigan Imputation Server (HRC v1.1) and genotyping data was linked to de-idenified EHR data. All available lab measurements in this cohort that occurred when the subject was at least 185 18 years of age. BioVU participants were selected based on available pathology report for liver biopsy in the note table in Observational Medical Outcomes Partnership (OMOP), excluding

53

those with other conflicting diagnoses (e.g. viral hepatitis, alcohol, transplant, explant). NAFLD
was defined based on pathology report defining hepatic fat as mild, moderate, severe, 5% or
more.

1190

1191 Control subjects within BloVU were identified by selecting those with ALT levels below 30 for 1192 males and below 20 for females. Both cases and controls were excluded for alcohol use 1193 disorders using ICD-9 and -10 codes.

1194

1195 Penn Medicine Biobank (PMBB): The Penn Medicine Biobank includes participants recruited 1196 from the University of Pennsylvania Health System. A total of 139 biopsy proven NAFLD cases 1197 were selected using Linguamatics natural language processing on biopsy protocols of the PENN 1198 EHR. Cases were then linked to the PennMedicine BioBank. In addition, 1,995 PMBB 1199 participants were classified as controls if a recent CT scan of the liver was available, but no 1200 steatosis was present. Appropriate consent was obtained from each participant regarding 1201 storage of biological specimens, genetic sequencing, and access to all available EHR data. DNA 1202 extracted from the blood plasma of 2,134 samples were genotyped in three batches: the 1203 Illumina QuadOmni chip at the Regeneron Genetics Center; the Illumina GSA V1 chip OR on the 1204 Illumina GSA V2 chip by the Center for Applied Genomics at the Children's Hospital of 1205 Philadelphia. Genotypes for each of the three PMBB datasets were imputed to the 1000 1206 Genomes reference panel (1000G Phase3 v5) using the Michigan Imputation Server. Results 1207 from liver biopsy data are shown in Supplemental Tables 6 and 7.

54

1209 Heritability estimates and genetic correlations analysis.

1210 LD-score regression was used to estimate the heritability coefficient, and subsequently 1211 population and sample prevalence estimates were applied to estimate heritability on the liability scale¹³². A genome-wide genetic correlation analysis was performed to investigate 1212 1213 possible co-regulation or a shared genetic basis between cALT and other complex traits and 1214 diseases (Supplementary Table 10). Pairwise genetic correlation coefficients were estimated 1215 between the meta-analyzed NAFLD GWAS summary output in EA and each of 774 precomputed 1216 and publicly available GWAS summary statistics for complex traits and diseases by using LD 1217 score regression through LD Hub v1.9.3 (http://ldsc.broadinstitute.org). Statistical significance was set to a Bonferroni-corrected level of $P < 6.5 \times 10^{-5}$. 1218

1219

1220 Tissue- and epigenetic-specific enrichment of NAFLD heritability.

1221 We analyzed cell type-specific annotations to identify enrichments of NAFLD heritability as 1222 shown in **Supplementary Table 16**. First, a baseline gene model was generated consisting of 53 functional categories, including UCSC gene models, ENCODE functional annotations¹³³, 1223 1224 Roadmap epigenomic annotations¹³⁴, and FANTOM5 enhancers¹³⁵. Gene expression and 1225 chromatin data were also analyzed to identify disease-relevant tissues, cell types, and tissuespecific epigenetic annotations. We used LDSC³⁷⁻³⁹ to test for enriched heritability in regions 1226 surrounding genes with the highest tissue-specific expression. Sources of data that were 1227 analyzed included 53 human tissue or cell type RNA-seg data from GTEx²⁸; human, mouse, or 1228 rat tissue or cell type array data from the Franke lab¹³⁶; 3 sets of mouse brain cell type array 1229 data from Cahoy et al^{137} ; 292 mouse immune cell type array data from ImmGen¹³⁸; and 396 1230

55

human epigenetic annotations from the Roadmap Epigenomics Consortium ¹³⁴. Expression
 profiles are considered statistically significantly enriched for T2D susceptibility if they pass the
 nominal P-value threshold of 0.001.

1234

1235 Pathway Annotation enrichment.

Enrichment analyses in DEPICT¹³⁹ were conducted using genome-wide significant (P < 5×10^{-8}) 1236 NAFLD GWAS lead SNPs (**Supplementary Table 18**). DEPICT is based on predefined phenotypic 1237 1238 gene sets from multiple databases and Affymetrix HGU133a2.0 expression microarray data from >37k subjects to build highly-expressed gene sets for Medical Subject Heading (MeSH) 1239 1240 tissue and cell type annotations. Output includes a P-value for enrichment and a yes/no 1241 indicator of whether the FDR q-value is significant (P < 0.05). Tissue and gene-set enrichment 1242 features are considered. We tested for epigenomic enrichment of genetic variants using GREGOR software (**Supplementary Table 19**)¹⁴⁰. We selected EA-specific NAFLD lead variants 1243 with a p-value less than 5×10^{-8} . We tested for enrichment of the resulting GWAS lead variants 1244 or their LD proxies (r² threshold of 0.8 within 1 Mb of the GWAS lead, 1000 Genomes Phase I) in 1245 1246 genomic features including ENCODE, Epigenome Roadmap, and manually curated data 1247 (Supplemental Table 20). Enrichment was considered significant if the enrichment p-value was less than the Bonferroni-corrected threshold of $P=1.8 \times 10^{-5}$ (0.05/2,725 tested features). 1248

1249

1250 Coding variant mapping.

1251 All imputed variants in MVP were evaluated with Ensemble variant effect predictor¹⁴¹, and all 1252 predicted LoF and missense variants were extracted. The LD was calculated with established

56

variants for trans-ancestry, EA, AA, and HISP lead SNPs based on 1000 Genomes reference panel¹⁴². For SNPs with low allele frequencies, the MVP dataset was used for LD calculation for the respective underlying population. For the trans-ancestry coding variants, the EA panel was used for LD calculation. Coding variants that were in strong LD ($r^2 > 0.7$) with lead SNPs and had a strong statistical association (P-value < $1x10^{-5}$) were considered the putative causal drivers of the observed association at the respective locus (**Supplementary Table 22**).

1259

- 1260
- 1261
- 1262 Colocalization with gene expression

GWAS summary statistics were lifted over from GRCh37 to GRCh38 using LiftOver 1263 1264 (https://genome.ucsc.edu/cgi-bin/hgLiftOver). Colocalization analysis was run separately for eQTLs and sQTLs for each of the 49 tissues in GTEx v8 (Supplementary Tables 23 and 24)²⁸. For 1265 each tissue, we obtained an LD block for the genome with a sentinel SNP at $P < 5x10^8$, and then 1266 1267 restricted analysis to the LD blocks. For each LD block with a sentinel SNP, all genes within 1Mb 1268 of the sentinel SNP (cis-Genes) were identified, and then restricted to those that were 1269 identified as eGenes in GTEx v8 at an FDR threshold of 0.05 (cis-eGenes). For each cis-eGene, 1270 we performed colocalization using all variants within 1Mb of the gene using the default prior probabilities in the 'coloc' function for the coloc package in R. We first assessed each coloc 1271 result for whether there was sufficient power to test for colocalization (PP3+PP4>0.8), and for 1272 1273 the colocalization pairs that pass the power threshold, we defined the significant colocalization 1274 threshold as PP4/(PP3+PP4)>0.9.

57

1275

1276 Overlap with open chromatin.

At each of the 77 NAFLD-associated loci from the trans-ancestry meta-analysis, we looked for overlaps between any variant in the credible set, and regions of open chromatin previously identified using ATAC-Seq experiments in two cell types—3 biological replicates of HepG2¹⁴³ and 3 biological replicates of hepatocyte-like cells (HLC)¹⁴⁴ produced by differentiating three biological replicates of iPSCs, which in turn were generated from peripheral blood mononuclear cells using a previously published protocol⁴⁴. Results are shown in **Supplementary Table 25**.

1283

1284 Overlap with Promoter Capture-C data.

1285 We used two promoter Capture-C datasets from two cell/tissue types to capture physical 1286 interactions between gene promoters and their regulatory elements and genes; three biological replicates of HepG2 liver carcinoma cells, and hepatocyte-like cells (HLC)¹⁴³. The detailed 1287 1288 protocol to prepare HepG2 or HLC cells for the promoter Capture-C experiment is previously described⁴⁴. Briefly, for each dataset, 10 million cells were used for promoter Capture-C library 1289 1290 generation. Custom capture baits were designed using an Agilent SureSelect library design 1291 targeting both ends of DpnII restriction fragments encompassing promoters (including 1292 alternative promoters) of all human coding genes, noncoding RNA, antisense RNA, snRNA, 1293 miRNA, snoRNA, and lincRNA transcripts, totaling 36,691 RNA baited fragments. Each library 1294 was then sequenced on an Illumina NovoSeq (HLC), or Illumina HiSeq 4000 (HLC), generating 1.6 billion read pairs per sample (50 base pair read length.) HiCUP¹⁴⁵ was used to process the 1295 raw FastQ files into loop calls; we then used CHiCAGO¹⁴⁶ to define significant looping 1296

58

interactions; a default score of 5 was defined as significant. We identified those NAFLD loci at
which at least one variant in the credible set interacted with an annotated bait in the Capture-C
data (Supplementary Table 25).

1301 Protein-Protein Interaction Network Analysis

We employed the search tool for retrieval of interacting genes (STRING) v11¹⁴⁷ (https://stringdb.org) to seek potential interactions between nominated genes. STRING integrates both known and predicted PPIs and can be applied to predict functional interactions of proteins. In our study, the sources for interaction were restricted to the 'Homo Sapiens' species and limited to experimentally validated and curated databases. An interaction score 2>20.4 were applied to construct the PPI networks, in which the nodes correspond to the proteins and the edges represent the interactions (Figure 4, Supplemental Table 26).

1309

1310 Ensemble variant-to-gene mapping to identify putative causal genes.

1311 Based on DEPICT gene prediction, coding variant linkage analysis, QTL analysis, and annotation 1312 enrichment, and PPI networks (Supplemental Tables 18-26), a total of 215 potentially relevant 1313 genes for NAFLD were mapped to trans-ancestry 77 loci. For each locus, we counted how many 1314 times each gene in that region was identified in the 8 analyses. We then divided this number by 1315 the total number of experiments (i.e., 8) to calculate an evidence burden (called nomination 1316 score) that ranges from 0 to 100%. For each genomic locus, the gene that was most frequently 1317 identified as a causal gene was selected as the putative causal gene for that locus. In the case of 1318 a tie break, and if the respective genes have identical nomination profiles, the gene with eQTLs

59

1319	in multiple tissues was selected as the putative causal gene. Similarly, gene nomination was
1320	preferred for loci that strongly tagged ($r^2 > 0.8$) a coding variant. Loci that scored with 3 distinct
1321	sources of evidence or greater are listed for coding variant (Table 1A) and non-coding variants
1322	(Table 1B), respectively.
1323	
1324	MVP LabWAS.
1325	A total of 21 continuous traits in the discovery MVP dataset, e.g. AST, ALP, fasting TG, HDL, LDL,
1326	TC, random glucose, HbA1c, albumin, bilirubin, platelet count, BMI, blood urea nitrogen (BUN),
1327	creatinine, eGFR, SBP, DBP, ESR, INR, and C-reactive protein were tested in 186,681 EA's with
1328	association of 77 SNPs using linear regression of log-linear values. Covariates included age,
1329	gender and the first 10 PC's of EA ancestry (Supplementary Table 29). The Bonferonni p-value
1330	threshold is set at 3.09x10 ⁻⁰⁵ (0.05 / 21 traits * 77 SNPs)
1331	
1332	PheWAS with UK Biobank data.
1333	For the 77 lead trans-ancestry SNPs and EA and AA specific SNPs, we performed a PheWAS in a
1334	genome-wide association study of EHR-derived ICD billing codes from the White British
1335	participants of the UK Biobank using PheWeb ¹⁴⁸ . In short, phenotypes were classified into 1,403
1336	PheWAS codes excluding SNP-PheWAS code association pairs with case counts less than fifty ¹⁴⁹ .
1337	All individuals were imputed using the Haplotype Reference Consortium panel ¹⁵⁰ , resulting in
1338	the availability of 28 million genetic variants for a total of 408,961 subjects. Analyses on binary
1339	outcomes were conducted using a model named SAIGE, adjusted for genetic relatedness,

60

Scalable and Accurate Implementation of GEneralized mixed model and represents a generalized mixed-model association test that accounts for case-control imbalance and sample relatedness¹⁵¹. Results are shown in **Supplemental Tables 30 and 31**. SNP-trait associations are listed if they passed a nominal significance threshold of P < 0.001, and are considered Bonferoni significant when P < 4.6×10^{-7} (0.05 / 77 SNPs * 1,403 traits).

1346

1347 IEU OpenGWAS project SNP lookup.

1348 An additional phenome-wide lookup was performed for 77 lead trans-ancestry SNPs and EA and AA specific SNPs in Bristol University's MRC Integrative Epidemiology Unit (IEU) GWAS 1349 database¹⁵². This database consists of 126,114,500,026 genetic associations from 34,494 GWAS 1350 1351 summary datasets, including UK Biobank (http://www.nealelab.is/uk-biobank), FinnGen 1352 (https://github.com/FINNGEN/pheweb), Biobank Japan (http://jenger.riken.jp/result), the NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas), a large-scale blood metabolites 1353 GWAS¹⁵³, circulating metabolites GWAS¹⁵⁴, the MR-Base manually curated database¹⁵⁵, and a 1354 protein level GWAS¹⁵⁶. Results are shown in **Supplemental Table 32**. 1355

1356

1357 Regional cardiometabolic cross-trait colocalization.

Bayesian colocalization tests between NAFLD-associated signals and the following trait- and disease-associated signals were performed using the COLOC R package¹⁵⁷. To enable cross-trait associations, we compiled summary statistics of 36 cardiometabolic and blood cell-related quantitative traits and disease from GWAS studies conducted in EA ancestry individuals, and for MVP-based reports also on AA and HISP. To summarize, for total, HDL, and LDL cholesterol,

61

1363 triglycerides, alcohol use disorder, alcohol intake, systolic blood pressure, diastolic blood 1364 pressure, type 2 diabetes, BMI, CAD, we used the summary statistics available from various MVP-based studies^{27,114,158}. Of these, the summary statistics for CAD and BMI GWAS in MVP 1365 1366 have not been published or deposited as of yet. Data on WHR were derived from GIANT Consortium¹⁵⁹, whereas summary statistics on CKD, gout, blood urea nitrogen, urate, urinary 1367 1368 albumin-to-creatinine ratio, microalbuminuria, and eGFR were derived from CKD Genetics Consortium¹⁶⁰⁻¹⁶². Finally, summary statistics of blood cell traits (e.g. platelet count, albumin, 1369 white blood cells, basophils, eosinophils, neutrophils, hemoglobin, hematocrit, immature 1370 1371 reticulocyte fraction, lymphocytes, monocytes, reticulocytes, mean corpuscular hemoglobin, 1372 mean corpuscular volume, mean platelet volume, platelet distribution width, and red cell 1373 distribution width) were derived from a large-scale GWAS report performed in UK Biobank and INTERVAL studies¹⁶³. A colocalization test was performed for all 77 NAFLD loci spanning 500kb 1374 region around the lead SNP for all 36 compiled traits. For each association pair COLOC was run 1375 1376 with default parameters and priors. COLOC computed posterior probabilities for the following 1377 five hypotheses: PPO, no association with trait 1 (cALT GWAS signal) or trait 2 (e.g., co-1378 associated metabolic signal); PP1, association with trait 1 only (i.e., no association with trait 2); 1379 PP2, association with trait 2 only (i.e., no association with trait 1); PP3, association with trait 1 1380 and trait 2 by two independent signals; and PP4, association with trait 1 and trait 2 by shared variants. Evidence of colocalization¹⁶⁴ was defined by PP3 + PP4 \ge 0.99 and PP4/PP3 \ge 5. Results 1381 1382 are shown in Supplemental Table 33.

1383

1384 Genetic risk scores and histologically characterized NAFLD.

62

1385 We constructed genetic risk scores (GRS) in 4 histologically characterized cohorts (e.g. 1386 Lundquist Whites and Hispanics, EPoS Consortium Whites, and BioVU Whites) by calculating a linear combination of weights derived from the MVP dataset of lead 77 trans-ancestry cALT 1387 variants that passed conventional genome-wide significance (GRS-77, P < 5.0x10⁻⁸). The GRS-77 1388 1389 was standardized and the risk of histologically characterized NAFLD was assessed using a 1390 logistic regression model together with the potential confounding factors of age, gender, and 1391 the first 3 to 5 principal components of ancestry. To delineate the potential driving effects of 1392 known NAFLD loci, we divided the 77 loci into two sets, and generated one PRS consisting of 7 1393 known NAFLD SNPs only (GRS-7), and one of newly identified 70 cALT SNPs (GRS-70). The goal 1394 of this separation is to evaluate whether a GRS based on novel SNPs alone (GRS-70) showed 1395 predictive capability for biopsy-proven histologically characterized NAFLD. Both GRS's were 1396 added as independents in a logistic regression model to explain histologically characterized NAFLD with the confounders of age, gender, and PC's of ancestry. The individual effect sizes for 1397 1398 each study were then meta-analyzed using the metagen package in R with random effects 1399 model comparing the standardized mean difference (Supplemental Table 9). Finally, a forest 1400 plot was created to visualize the effect estimates between the studies (Supplemental Figure 8).

1401

1402 Transcription Factor Analysis.

We identified nominated genes (**Supplemental Table 28**) that encode for TFs based on known motifs, inferred motifs from similar proteins, and likely sequence specific TFs according to literature or domain structure¹⁶⁵. Target genes for these TFs were extracted using DoRothEA database¹⁶⁶ in OmniPath collection¹⁶⁷ using the associated Bioconductor R package

63

1407 OmnipathR¹⁶⁸, a gene set resource containing TF-TF target interactions curated from public 1408 literature resources, such as ChIP-seq peaks, TF binding site motifs and interactions inferred 1409 directly from gene expression.

1410

1411 Acknowledgements

1412 This research is based on data from the Million Veteran Program, Office of Research and 1413 Development, Veterans Health Administration and was supported by award no. MVP000. This 1414 publication does not represent the views of the Department of Veterans Affairs, the US Food 1415 and Drug Administration, or the US Government. This research was also supported by funding 1416 from: the Department of Veterans Affairs awards 101- BX003362 (P.S.T. and K.M.C) and 1417 IO1BX003341 (H.R.K. Co-Principal Investigator) and the VA Informatics and Computing 1418 Infrastructure (VINCI) VA HSR RES 130457 (S.L.D). B.F.V. acknowledges support for this work 1419 from the NIH/NIDDK (DK101478 and DK126194) and a Linda Pechenik Montague Investigator 1420 award. K.M.C, S.M.D, J.M.G, C.J.O, L.S.P, and P.S.T. are supported by the VA Cooperative Studies 1421 Program. S.M.D. is supported by the Veterans Administration [IK2 CX001780]. Funding support 1422 is also acknowledged for M.S. (K23 DK115897), R.M.C (R01 AA026302), D.K. (National Heart, 1423 Lung, and Blood Institute of the National Institutes of Health [T32 HL007734]), J.B.M. 1424 (R01HL151855, UM1DK078616), L.S.P. (VA awards IO1 CX001025, and IO1 CX001737, NIH 1425 awards R21 DK099716, U01 DK091958, U01 DK098246, P30 DK111024, and R03 A|133172, and 1426 a Cystic Fibrosis Foundation award PHILLI12AO). The Rader lab was supported by NIH grants 1427 HL134853 (NJH and DJR) and DK114291-01A1 (K.T.C, N.J.H, and D.J.R). We thank all study 1428 participants for their contribution. Support for imaging studies was provided by ITMAT (NIH

64

NCATS UL1TR001878), the Penn Center for Precision Medicine Accelerator Fund and R01 HL137501. Data for external replication and hepatic fat concordance were provided by investigators using United Kingdom BioBank, Multi-Ethnic Study of Atherosclerosis (MESA), Old Order Amish Study (Amish), Framingham Heart Study (FHS) and Penn Medicine Biobank (PMBB).

1434

1435 MESA/MESA SHARe Acknowledgements: MESA and the MESA SHARe projects are conducted 1436 and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with 1437 MESA investigators. This research was supported by R01 HL071739 and MESA was supported 1438 by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-1439 HC-95160, 75N92020D00002. N01-HC-95161, 75N92020D00003. N01-HC-95162. 1440 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-1441 HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-1442 TR-001079, UL1-TR-001420. Also supported in part by the National Center for Advancing 1443 Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and 1444 Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern 1445 California Diabetes Endocrinology Research Center.

1446

NASH CRN Acknowledgements: The NASH Boys study was supported by NIDDK (U01DK061734,
U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061737, U01DK061738,
U01DK061730, U01DK061713) and NICHD. It was also supported by NIH CTSA awards
(UL1TR000040, UL1RR024989, UL1RR025761, M01RR00188, UL1RR024131, UL1RR025014,

65

1451 UL1RR031990, UL1RR025741, UL1RR029887, UL1RR24156, UL1RR025055, UL1RR031980), and 1452 DRC HDK063491. LQTS was supported by the National Institutes of Health (grant 1453 5R42HL112435-04 to QT Medical, Inc.). The provision of genotyping data was supported in part 1454 by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the 1455 National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) 1456 grant DK063491 to the Southern California Diabetes Endocrinology Research Center. For LQTS: 1457 QT Medical, Inc., was involved in the study design and collection of data. However, QT Medical, Inc., had no involvement in the analysis and interpretation of the data, the drafting of the 1458 1459 article, or the decision to submit the article for publication. The FLINT trial was conducted by 1460 the NASH CRN and supported in part by a Collaborative Research and Development Agreement 1461 (CRADA) between NIDDK and Intercept Pharmaceuticals. The Nonalcoholic Steatohepatitis 1462 Clinical Research Network (NASH CRN) is supported by the National Institute of Diabetes and 1463 Digestive and Kidney Diseases (NIDDK) (grants U01DK061718, U01DK061728, U01DK061731, 1464 U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713). 1465 Additional support is received from the National Center for Advancing Translational Sciences (NCATS) (grants UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, 1466 1467 UL1TR000004, UL1TR000423, UL1TR000058). The PIVENS study was supported by grants from 1468 the National Institutes of Health to the NASH Clinical Research Network (U01DK61718, 1469 U01DK61732, U01DK61734, U01DK61728, U01DK61731, U01DK61737, U01DK61738. 1470 U01DK61730, U01DK61713) and, in part, by the intramural program on the NIH, National 1471 Cancer Institute. Other grant support includes the following National Institutes of Health General Clinical Research Centers or Clinical and Translational Science Awards: UL1RR024989. 1472

66

1473 UL1RR024128, M01RR000750, UL1RR024131, M01RR000827, UL1RR025014, M01RR000065. 1474 Additional funding to conduct PIVENS trial was provided by Takeda Pharmaceuticals North 1475 America, Inc. through a Cooperative Research and Development Agreement (CRADA) with the 1476 National Institutes of Health. The vitamin E softgels and matching placebo were provided by 1477 Pharmavite, LLC through a Clinical Trial Agreement with the National Institutes of Health. The 1478 NASH women study was supported by U01DK061737 and K24DK069290 (N.C.), NCRR grant 1479 M01-RR00425 to the Cedars-Sinai General Research Center Genotyping core, P30DK063491 to 1480 J.R., and R01DK079888 to M.O.G. This work is supported in part by the American 1481 Gastroenterological Association (AGA) Foundation, Sucampo, ASP Designated Research Award in Geriatric Gastroenterology, and by a T. Franklin Williams Scholarship Award; Funding 1482 1483 provided by Atlantic Philanthropies, Inc, the John A. Hartford Foundation, the Association of 1484 Specialty Professors, and the American Gastroenterological Association to R.L. This research 1485 was funded in part with the support of the UCSD Digestive Diseases Research Development 1486 Center, US PHS grant DK080506.

1487 The CAP study was supported by the National Institutes of Health: grant U19 HL069757 from 1488 the National Heart, Lung, and Blood Institute; and grant UL1TR000124 from the National Center 1489 for Advancing Translational Sciences.

1490

1491 **EPoS Acknowledgements:** The EPoS genetics study and the European NAFLD Registry haves 1492 been supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by 1493 the European Union Horizon 2020 Framework Program of the European Union under Grant 1494 Agreement 634413, the FLIP (Fatty Liver: Inhibition of Progression) consortium funded by the

67

1495	(European Union FP7 under grant agreement 241762), the LITMUS (Liver Investigation: Testing
1496	Marker Utility in Steatohepatitis) consortium funded by the European Union Innovative
1497	Medicines Initiative 2 Joint Undertaking that receives support from the European Union's
1498	Horizon 2020 research and innovation programme and EFPIA under grant agreement 777377,
1499	and the Newcastle NIHR Biomedical Research Centre.
1500	
1501	Gilead Acknowledgements: The Stellar and Atlas were funded by Gilead Sciences, Inc.
1502	
1503	Regeneron Acknowledgements: The Geisinger Health System bariatric-surgery biobank was
1504	funded by Regeneron Pharmaceuticals and partly supported by a grant (P30DK072488) from
1505	the Mid-Atlantic Nutrition Obesity Research Center by the National Institutes of Health (NIH).
1506	
1507	Penn Medicine Biobank Acknowledgements: The Penn Medicine BioBank is funded by the
1508	Perelman School of Medicine at the University of Pennsylvania and by a gift from the Smilow
1509	family, and the National Center for Advancing Translational Sciences of the National Institutes

1510 of Health under CTSA Award Number UL1TR001878."

1511

BioVU Acknowledgements: The Vanderbilt University Medical Center's BioVU projects are supported by institutional funding, private agencies, and federal grants, which include the NIH funded Shared Instrumentation Grant S100D017985 and S10RR025141; CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975; and investigator-led projects U01HG004798,

68

1516	R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711;
1517	U01 HG004603; U01 HG006378.
1518	
1519	Ethics statement
1520	The Central Veterans Affairs Institutional Review Board (IRB) and site-specific Research and
1521	Development Committees approved the Million Veteran Program study. All other cohorts
1522	participating in this meta-analysis have ethical approval from their local institutions. All relevant
1523	ethical regulations were followed.
1524 1525	Data availability
1526	The full summary level association data from the trans-ancestry, European, African American,
1527	Hispanic, and Asian meta-analysis from this report will be available through dbGAP (Accession
1528	codes will be available before publication).
1529	
1530	Disclosures
1531	H.R.K. is a member of a Dicerna scientific advisory board; a member of the American Society of
1532	Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which during the past three
1533	years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna,
1534	Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka; and is named as an inventor on PCT
1535	patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed
1536	January 24, 2018. D.G. is employed part-time by Novo Nordisk.